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Factors currently at the forefront of human in vitro fertilization (IVF) that collectively 
influence treatment success in the form of blastocysts development were investigated during 
early mammalian embryology with concentration on infertile patients presenting with diminished 
ovarian reserve or preliminary ovarian failure. A novel experimental technique, graft transplant-
embryonic stem cells (GT-ESC) was introduced in the mouse model, as the first inclusive 
approach for embryo selection in IVF treatments resulting in successful graft integration of 
sibling cells, stage-dependent (day 4) blastocysts. E-Cadherin-catenin bonds play an integral role 
in trophectoderm cell viability and calcium removal, inducing disruption of cell-to-cell bonds at 
the blastocyst stage was detrimental to continued blastocyst development. One of the leading 
methods for embryo selection for uterine transfer in human IVF is application of pre-
implantation genetic screening (PGS) methods such as next generation sequencing (NGS). 
Female patients <35 y do not benefit from this treatment when outcome is measured by presence 
of fetal heart beats at 10 weeks of gestation. Patients 35-37 y benefit from PGS with no 
significant difference of outcome based on form of PGS method utilized. Therefore, small 
nucleotide polymorphism array (snp-array) or targeted-NGS should be selected for this age range 
to lessen the financial burden of the patient. Embryos from women >40 y have a higher rate of 
mosaic cell lines which can be detected by NGS. Therefore NGS is most beneficial for women 
>40 y. Additionally, ovarian stimulation of the patient during human IVF can notably influence 
outcome. Anti-Müllerian hormone (AMH) is a more conducive indicator of blastocysts 
development per treatment compared to basal follicle stimulating hormone (FSH). Actionable 
 
variables included in a decision tree analysis determined a negative influence (0% success, n=11) 
of high dose gonadotropin use (>3325 IUs) in good prognosis patients (>12 mature follicles at 
trigger, AMH >3.15 ng/mL). A positive relationship exists (80% success, n=11) between poor 
responders (AMH <1.78 ng/mL, <12 mature follicles at trigger) and high dose gonadotropin use 
(>3025 IUs). Utilizing the decision tree during IVF treatment can be beneficial to treatment 
success.  Moreover, a parallel relationship of the fundamental principles of culture medium pH, 
pCO2 and pO2 was found with respect to blastocyst development. Human infertility patients’ 
gametes predisposed to primary stressors (i.e., age, genetics and etiology) are negatively 
impacted (~30% success, n=7) for cleavage stage (day 3) embryo development when primary 
culture medium has pCO2 <30mmHg given age >31 y and <14 oocytes retrieved. When day 3 
embryo development is measured at >65% good quality embryos per treatment (based on SART 
grading criteria), blastocysts development success is highest when secondary culture medium 
pO2 is 69-88 mmHg (~90% success, n=12). Thus, IVF treatment outcome can be optimized with 
utilization of predictive model analyses in the form of decision trees providing greater success 
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1.1 Central Theme/Background 
Conception occurs naturally for many women. However, for many others in vitro 
fertilization (IVF) may be required. An average of 7.3 million women in the United States have 
used infertility services reported to the centers of disease control (CDC), which is 7.3% of married 
women aged 15-44y (“FastStats” 2017). During a menstrual cycle that is regulated by hormones, 
such as follicle stimulating hormone, luteinizing hormone, estradiol and progesterone, a follicle 
matures and the mature oocyte is released from the ovary. Upon ovulation, the oocyte is fertilized 
in the fallopian tube and the resulting embryo continues to divide and implant in the uterus, 
creating a pregnancy. The embryo develops into a placenta and a fetus, ultimately leading to a live 
born infant. When there are problems or complications associated with the reproductive health of 
women, assisted reproductive technology services (ART) are often used. Some examples of such 
complications include advanced maternal age (related to diminished ovarian reserve), premature 
ovarian failure (POF) and poly-cystic ovary disease. One of the solutions that ART offers is in 
vitro fertilization (IVF). In this process, many of the complications mentioned above are overcome 
by the use of controlled ovarian hyperstimulation which allows for the development of multiple 
embryos. This leads to excess embryo development for some women while others experience low 
to no embryo development. Two of the leading conditions for the latter group of patients involve 
women with diminished ovarian reserve or preliminary ovarian failure. 
Diminished ovarian reserve (DOR) is a condition characterized by poor fertility outcomes 
and currently presents as a major challenge in reproductive medicine, particularly in vitro 
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fertilization (IVF) (Cohen et al. 2015; Atasever et al. 2016; Levi et al. 2001).  Women are 
diagnosed with DOR if they demonstrate at least one of the following:  
• High follicle stimulating hormone (FSH) levels when not in the follicular phase
• Low antral follicle counts
• Low anti-Müllerian hormone (AMH)
When diagnostic testing is performed to aid in the diagnosis and treatment of women who 
wish to bear children, routine tests including serum hormone assays and ovarian ultrasounds are 
performed. When a woman is in her reproductive years with good prognosis, her FSH is expected 
to be between 3.1-7.9 mIU/ml (Atasever et al. 2016; Ryley et al. 2005; Abdalla 2004). AMH is 
used to assess the remaining ovarian reserve of a female as well as a predictor of her response to 
controlled hyperstimulation of the ovaries during IVF treatment and her AMH is expected to be 
≥1 ng/ml.  
Diminished ovarian reserve patients often use assisted reproductive technology to increase 
their chances of a successful pregnancy. The Center for Disease Control’s (CDC) national assisted 
reproductive technology surveillance system report for 2013 confirms US clinics performed 
190,773 IVF procedures that year. A remarkable 32% of patients within this group were diagnosed 
with DOR (National ART Summary Report for 2013.). This subgroup of patients seeking infertility 
treatments are composed of women that have advanced maternal age, defined as 38 years or older 
or premature ovarian failure (POF). Premature ovarian failure is defined as a condition in which a 
woman’s ovaries enter early menopause due to amenorrhea, hypergonadotropism and 
hypoestrogenism or genetic reasons. One such genetic disorder is fragile-X, which is a single gene 
disorder that can cause 20% of women who are carriers to enter early menopause before the age 
of 40 (Santoro et al. 2012; Saldarriaga et al. 2014.; Chapman et al. 2015). In today’s society, 
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women are more active and valuable in the work force. As a result, families opt to delay child 
bearing until they are satisfied in their career achievements. With female age, fertility declines. 
IVF, the solution to the increasing rate of infertility is not perfect. Some of its problems are now 
discussed. 
 
1.2 Statement of the Problem 
IVF is the primary treatment offered to patients of advanced maternal age and diminished 
ovarian reserve.  IVF is preceded by controlled hyperstimulation of the ovaries by the use of 
recombinant gonadotropins such as FSH and luteinizing hormone (LH). These are the two main 
stimulatory agents used by most reproductive endocrinologists in the United States (Pouwer et al. 
2015; Muasher et al. 1988; Farquhar et al. 2013). The leading benefit of controlled ovarian 
hyperstimulation is the production and retrieval of many oocytes per IVF treatment with an 
opportunity of increased pregnancy rates due to the creation of multiple embryos. Yet, IVF has not 
reached a high efficiency when considering the number of oocytes retrieved and the resulting high 
quality implantable blastocysts that develop from them. This is one of the major problems in the 
IVF industry and the proposed studies here give valuable information on improved culture 
conditions leading to higher pregnancy rates as well as introduction of a micromanipulation 
technique that could possibly lead to reduced embryo discard rate.  
Many more oocytes are produced per IVF treatment and fertilized than the number of 
children the family intends to have. However, currently roughly 60% of fertilized oocytes develop 
into blastocysts, which are defined as embryos at the 5th day of development and have two 
differentiated cell types, (discussed in Embryo Development section). Approximately half may be 
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suitable for uterine transfer or cryopreservation, defined as high quality blastocysts1 (Zhao et al. 
2012; Costa-Borges et al. 2016). Often, IVF treatments for women over the age of 35 years, 
embryos are observed to be of poor quality in either one of the cell types. Meanwhile, the other 
cell type may be fair to good quality. Embryos that demonstrate this form of “mixed quality” 
development are discarded due to poor grading per standard operating protocol in IVF laboratories. 
In patients that are characterized as DOR, their number of oocytes produced per IVF treatment is 
usually lower than 8, with only 80% expected to be mature for fertilization (Hariton et al. 2017; 
Broer et al. 2011; Lai et al. 2013). By day 5 post fertilization just 2-3 may develop into blastocysts. 
Due to the poor prognosis of this group of infertility patients, often times the few blastocysts that 
develop are not suitable for uterine transfer or cryopreservation, rendering the IVF treatment a 
failed attempt. To propose a solution, the underlying DOR and POF conditions as well as 
embryonic development should be well understood and is discussed in the next sections.  
 
1.3 Review of Literature 
IVF success relies on many aspects of developmental and genetic biology. Some of the 
many important aspects are infertility conditions such as diminished ovarian reserve and 
preliminary ovarian failure as well as developmental aspects such as in vitro culture conditions, 
embryonic cell differentiation, and genetic anomalies such chimeric growth. The following 
sections review many of the factors that contribute to the success of IVF treatments for infertility 
patients.  
                                                 
1.  High quality blastocyst is a common term that is used by embryologists to signify that an embryo has been graded 
in a subjective manner and determined to be of high implantation potential based solely on its morphology at the time 
of grading. Different grading systems are used by laboratories. The grading system used in my studies is the SART 
Grading System (Racowsky et al. 2010). 
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 Embryo Development  
An embryo is created when a sperm cell successfully fertilizes an oocyte. This event marks 
the beginning of embryo development referenced as day 1. Upon fertilization, pronuclei appear 
and are visible between 16-19 hours post fertilization the first cell differentiation occurs by day 4 
of embryonic development. This is the stage where a ≥8 cell embryo forms a morula, a compacted 
mass of cells, an event unique to mammalian embryo development (Piccolomini et al. 2016; Nikas 
et al. 1996; Pera and Prezzoto 2016). The cells that are compacted on the inner surface of that 
sphere then differentiate into inner cell mass. The cells that are touching the inner cells on one side 
of their surface and have no neighboring cells on the other side, then develop into trophoblast or 
trophectoderm cells (Pera and Prezzoto 2016). Once the compaction is complete, the embryo then 
begins to collect fluid from its environment and a cavity called a blastocoel begins to form as seen 
in figure 1.1a. This blastocoel continues to grow in size as the embryo collects more fluid.  
Approximately 5 days post fertilization, human embryos (called “blastocysts” at this stage) 
have differentiated in two cell types: inner cell mass (ICM) and trophectoderm (TE) (Ivec et al. 
2011; Mihajlović et al. 2015; Bavister 2012). This is the first binary differentiation in mammalian 
development. Prior to blastocyst formation, each embryonic blastomere expresses both the Cdx2 
and Oct4 transcriptional factors, which allow the cell to become trophoblast or ICM cells (Gilbert 
2014). Upon differentiation, the cell expresses a set of genes specific to each region. Only 
trophoblast cells make Cdx2 and down regulate Nanog and Oct4 transcriptional factors. Cdx2 is 
only synthesized in the trophoblast cells forcing the down-regulation of Oct 4 and Nanog. Cdx2 
activation is regulated by Yap protein which in turn is a co-factor for the transcription co-factor 
Tead4. Phosphorylated Yap cannot enter the nucleus and is degraded. The ICM cells Tead4 cannot 
function and Cdx2 remains untranscribed. Cdx2 blocks the expression of Oct4 and Oct4 blocks 
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the expression of Cdx2.In this way, the two cell types remain differentiated. This binary 
differentiation is a result of ICM cells are the group of cells that form the fetus, while the TE cells 
mainly develop into a placenta and cord (figure 1.1b). On day 6 of embryo development, the TE 
cells stretch while expanding and the zona pellucida that encompasses the embryo thins and tears 
allowing for hatching of the embryo (Lee et al. 2016). Once completely hatched, the embryo will 
come into contact with the uterus and the process of implantation will start (Ruane et al. 2017; Teh 
et al. 2016; Watson 1992), discussed in the next section. 
 
Figure 1.1. Human embryo development. A). On day 1, fertilization can be confirmed by the two 
visible pronuclei. On day 3 of development, the embryo has divided into 6-8 cells. By day 4, cell 
division continues and the cells compact to form a morula. On day 5, the embryo has cavitated and 
a cavity called a blastocoel has been created. Cells have differentiated into inner cell mass and 
trophectoderm cells. Courtesy: Dallas IVF. B). Human blastocyst. This blastocyst is at 5 days post 
fertilization. The diameter is approximately 250μm. The blastocyst is completely expanded 
containing a fluid filled blastocoel and the inner cell mass (ICM), outlined in red, is easily 
distinguishable from the trophectoderm (TE) cells. Three of the TE cells are traced in red against 
the zona pellucida. Courtesy: Dallas IVF 
 
 Placenta and Fetus 
On day 5 of development, an embryo begins the process of implantation in the uterus. The 
first step of this process is called apposition, which is defined by the embryo embedding into the 
A) B) 
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endometrium (Ruane et al. 2017; Teh 2016). Ruane et al. (2017) went on to state that during this 
step, between days 5-8 of development, the trophoblast cells continue to multiply and during the 
process evade into the endometrial tissue. The complete evasion of the cells into the endometrium 
is called adhesion. The endometrial tissue grows over the developing embryo to completely coat 
it. At the same time, the pools of blood, supplied by the maternal vessels seen in figure 1.2, in the 
uterine lining that are being supported by blood vessels in the uterus begin to coalesce. The 
trophoblast cells are continuing to multiply and some of them between days 7-12 of development, 
fuse together to form large sheaths of multinucleated cells called the syncytiotrophoblasts. 
Between days 12-18, these sheaths continue to grow and extend into the endometrium to make 
fingerlike projections called the villi. The trophoblast cells that have not participated in the fusion 
are now called cytotrophoblasts. Inside the villi the fetal blood vessels develop (Evans et al. 2016). 
By day 23, the pools of blood in the uterus have fused together in between the villi and are in close 
contact, but not fused together due to the membrane of trophoblast in between them. It is now that 
the nutrients from the uterine blood can diffuse into the fetal blood and the waste products from 
the fetal blood can diffuse out to the uterine blood (Zohni et al. 2016; Carter and Enders 2016). 
The structure continues to grow during the pregnancy, to a point where it lines almost the entire 
depth of the uterus and as it grows, more nutrients can be diffused across. This structure matures 
into a placenta (Atlas de Reproducción Asistida 2014). 
The placenta has many functions. Mainly, it ensures the adequate blood supply for the fetal-
placental unit to have exchange of nutrients, oxygen and wastes between the mother and the fetus 
(Acharya et al. 2016). It also protects the developing fetus from the maternal immune system 
attack. The placenta anchors the embryonic and extra embryonic structures of the blastocyst to the 
uterine wall and releases hormones such as progesterone, estrogen, and chorionic gonadotropin 
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(hCG) (Handwerger and Freemark 2000). These hormones, amongst others, are essential to fetal 
life. Progesterone supports embryo implantation by stimulating an increased amount of human 
chorionic gonadotropin (hGC) secretions necessary for fetal nutrition. Human chorionic 
gonadotropin is a protein hormone that is similar in structure to the luteinizing hormone. 
 
Figure 1.2. Placental structure. The organization for the blood vessels in the placenta can be seen 
here. The maternal vessels provide a pool of nutrient rich oxygenated blood to surround the villus, 
which carries fetal blood. The thin layer of cells separating the mother’s blood from fetal blood is 
formed from the trophectoderm cells. Source:  Henry Vandyke Carter - Henry Gray (1918) 
Anatomy of the Human Body. 
 
In the early pregnancy its primary role is to keep the corpus luteum functioning so it can continue 
to produce estrogen and progesterone (Kayisli et al. 2003). Later in pregnancy, it may have an 
anti-body effect, which is thought to protect the fetus from being rejected by the mother’s body. It 
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is also the hormone that allows the testes to grow by the production of testosterone. Elevated levels 
of progesterone are necessary to prevent spontaneous abortion and contractions of the uterus 
(Andersen et al. 2016). Estrogen is crucial for the process of proliferation (Evans et al. 2016). This 
study went on to state that estrogen is responsible for the enlargement of the uterus to allow growth 
of the fetus and the enlargement of breasts for the production of milk. Elevated levels of estrogen 
will also increase blood supply towards the end of pregnancy through a process called 
vasodilatation (Corcoran et al. 2014; Wang and Zhao 2010). 
The placenta connects to the fetus by the umbilical cord through the abdomen (figure 1.3).  
 
Figure 1.3. Fetal circulation plan. One of the branches joins with the hepatic portal vein connecting 
it to its left branch carrying blood to the liver. The ductus venosus, second branch bypasses the 
liver to flow into the inferior vena cava, which carries fetal blood towards the heart. Source: 
Anatomy of the Human Body, 2000 
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The cord has an umbilical vein that continues towards the liver where it splits into two branches. 
One of the branches joins with the hepatic portal vein connecting it to its left branch carrying blood 
to the liver. The second branch is known as the ductus venosus and bypasses the liver to flow into 
the inferior vena cava, which carries fetal blood towards the heart.  There are two umbilical arteries 
that branch from the internal iliac arteries and pass on each side of the bladder back into the 
umbilical cord to complete the circulation into the placenta (Gray 2000; Wang and Zhao 2010). It 
is clear that this is where the placenta and the fetus interact making this the critical developmental 
aspect of the growing embryo that may cause complications with the success of the novel technique 
introduced in this research (Chapter 3).  
Mentioned earlier, some women experience infertility. Two of the conditions that lead to 
infertility are diminished ovarian reserve and preliminary ovarian failure. These conditions are 
now discussed. 
 
 Diminished Ovarian Reserve 
Women with true diminished ovarian reserve are a large part of the IVF programs in the 
United States (“National ART Summary Report for 2013” 2015; Cohen et al. 2015). Many fertility 
centers will often refuse treatment to this group of patients with their own oocytes due to the 
extremely poor prognosis (Lamazou et al. 2012; Ethics Committee of American Society for 
Reproductive Medicine 2012). There are smaller IVF programs that will offer a reduced multi-
IVF treatment program to this group of patients, which financially helps the patient and the IVF 
center (Mathews et al. 2009; Ben-Rafael and Feldberg 1993). On the other hand, multiple 
treatments of injectable gonadotropins and a hyperstimulated, super physiological state of the 
female patient places her at risk for thrombosis and ovarian hyperstimulation syndrome amongst 
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other things (Sousa et al. 2015). Even with multiple treatments the programs can only offer a small 
insignificant number of pregnancies and live birth in this category (Vega et al. 2016; Ben-Rafael 
and Feldberg 1993; Oehninger 2011).  
Preliminary ovarian failure (POF) is one of the conditions that lead to DOR (Alborzi et al. 
2015). POF represents a condition, which is characterized by the absence of normal ovarian 
function due to the depletion of primordial follicles before the age of 40 years (Butts et al. 2013). 
With this condition women are reported to have amenorrhea. Other symptoms usually include 
arrhythmia, intolerance and hot flashes (Broekmans et al. 2009; Butts et al. 2013). An accurate 
clinical diagnosis can be made if there is an absence of menses for at least 4 months in combination 
with FSH levels exceeding 40 IU/L before the age of 40 years (Safdarian et al. 2012). 
The aging ovary goes through a series of hypothalamic-pituitary-ovarian axis irregularity. 
This is a negative feedback system of pulsatile gonadotropins secretion. Studies in postmenopausal 
women compared with premenopausal women have shown elevated LH and FSH levels and 
increased LH pulse amplitudes without a change in LH frequency (Gill et al. 2002; Barroso et al. 
2001). This altered feedback of aging ovaries may be due to a lack of steroid priming and the result 
of ovarian factors. With elevating FSH levels, a higher number of antral follicles are grown to 
dominant follicles along with a larger cohort of recruitment per menstrual cycle. This is the leading 
reason for dizigotic twinning as well as early stages of menopause. With each passing menstrual 
cycle the number or remaining follicles are lessened and women presenting with DOR or POF are 
then facing infertility. With a correct diagnosis, the option of IVF is usually pursued. According 
to the Society of Assisted Reproductive Technology (SART), the most current data, which includes 
live births is published for 2014. A total of 190,384 treatments were performed that year. Figure 
1.4 reflects the percentage of treatments resulting in live births per age category with an average 
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of only 23% of embryo transfers resulting in viable babies delivered. This data reports only those 
treatments resulting in viable embryos for transfer. Treatments in which embryos were not 
transferred due to no blastocyst development, oocyte banking, embryo banking or complete arrest 
in development are not reported. Furthermore, it is clearly observed here that there is a steep 
decline in success rates after the age of 40 years. The patients that have the least chances of success 
are in the age category of greater than 42 years with success of 4% per IVF treatment. The only 
method to improve this outcome currently is with the use of donor oocytes. 
 
Figure 1.4. National IVF success rates for 2014.  A total of 190,384 treatments were performed 
that year. The figure reflects the percentage of treatments resulting in live births per age category, 
stating that average of only 23% of embryo transfers resulted in viable babies delivered.  
Source: https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0 
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years from 1970 to 2006 according to the data collected by the centers of disease control (Mathews 
et al. 2009). With the accepted use of contraceptives and awareness of timed treatments, unplanned 
pregnancies occur less often. There can be benefits to delaying child-bearing; however it can make 
it more difficult for a woman with increased age to conceive naturally as age can affect fertility, 
pregnancy and childbirth. A woman’s fertility begins to decline at a much faster rate at 36 years 
of age and varies from woman to woman (Hart 2016; Meldrum et al. 2016; Broekmans et al. 2009). 
Currently there is no guaranteed method that will estimate when this will be for a particular woman 
or any symptoms that arise to warm the onset of this decline.  
The gradual change in fertility is due to a decrease in the number and quality of oocytes 
remaining in the ovaries (Sauer 2015). As the age increases so does follicle stimulating hormone 
(FSH) levels causing more antral follicles to grow and arrest per menstrual cycle than a woman 
with a normal range FSH level. This causes the higher rate of declining ovarian reserve (Cohen et 
al. 2015). This event is well correlated to the decline in the quality of oocytes remaining. Increased 
female age will result in a lowered percent of chromosomally balanced oocytes, increasing the 
chances of early miscarriage or a pregnancy with an aneuploid fetus (Stoop et al. 2014; Shahine et 
al. 2016; Staessen et al. 2008). Also associated with increased age is the increased risk of ectopic 
pregnancy, preeclampsia, hypertension, gestation diabetes, placental complications, intrauterine 
growth restriction, and birth by cesarean section. Babies born may have lower birth weight and 
non-genetic malformation (Reproductive Endocrinology and Infertility Committee 2011).  
Fertility treatments are desired mostly by patients that are unsuccessful at achieving a 
pregnancy within the first 6 months of trying to conceive when under 35 years of age and within 
the first 12 months when over the age of 35 years (Aghajanova et al. 2016; Gnoth et al. 2003). 
Medical treatments cannot make up for the age related fertility decline, however can offer 
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treatment that increases the chances of a successful pregnancy by the use of assisted reproductive 
technology (ART). Diagnosis are formulated with the combination of female partner’s age, 
medical history, sperm parameters, uterine lining assessment, fallopian tube assessment, serum 
hormone assays and more. These treatments can be invasive and expensive and have undesired 
side effects or complications (Humaidan et al. 2016). In vitro fertilization is the most effective 
method amongst ART treatments. Mentioned earlier, in 2013 the number of IVF treatments that 
comprised of women diagnosed with DOR was approximately 61,000. This subset of patients is 
also one that results in the lowest success in IVF due to lowered number and quality of blastocysts 
created per IVF treatment and the increased odds of no uterine transfer of embryos due to no 
blastocyst development or poor blastocyst development. As the percentage of women with DOR, 
advanced maternal age (AMA) or POF increases each year, there is growing need of the 
understanding cell culture of gametes and embryos, particularly blastocysts.  
IVF is utilized in many different species such as equine for horse breeding, bovine for 
cattle, mouse for research and human for infertility (Wheeler and Rubessa 2016; Mugnier et al. 
2009; An et al. 2017; Feuer et al. 2014). The leading benefit of the treatment is the opportunity of 
increased pregnancy rates due to the creation of multiple embryos per IVF treatment. Embryos 
created during such treatments are discarded if development is poor in the trophectoderm or inner 
cell mass (ICM) cells. The introduction of the mechanical approach this research aims to decrease 
the number of embryos discarded by utilizing a method that allows for proliferation and adhesion 
of trophectoderm cells of sibling blastocysts. Ultimately the number of high quality embryos per 
IVF treatment will be higher, in turn saving embryos that would otherwise be destined for discard. 
The understanding of response and development when studied in Mus musculus provide 
preliminary evidence and influence the need for study and clinical trials in human IVF.  
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There are many organisms that have been investigated for embryonic graft transplants 
including fish and amphibians, where grafts of the embryonic tissue from one embryo were 
introduced into the developing second embryo of a slightly different and species. For example, 
grafts of mice embryonic stem cells (ES) into the embryonic stem cells of a rat, which develop 
into a chimera of both species (Kidder et al. 2008) have been studied for the purposes of disease 
modeling and the investigation of transgenerational gene expression and epigenetics of gene 
expression. There is currently no federal funding available for human embryonic stem cell studies, 
which has limited the transitional studies from lower mammalian species of embryos to develop 
into human trials. Likely as a consequence, no work has been reported involving rescue of poor 
quality embryos with graft of TE tissue.  
There are baseline diagnostic tests performed routinely by assessing hormone levels in the 
blood serum. Two of the hormones used to aid in diagnosis of DOR and preliminary ovarian failure 
are anti-Müllerian hormone and follicle stimulating hormone.  
 
1.3.3.1 Anti-Müllerian Hormone 
Anti-Müllerian hormone (AMH) is a gonadal hormone, member of the TGF-β super family 
of growth and differentiation factors like inhibins and activins (Koskela and Tapanainen 2016). 
AMH was initially referred to as Müllerian-inhibiting substance (MIS) and has been known for its 
role in sexual differentiation since the 1940s (Wilson et al. 1981; Broer et al. 2014; Weenen et al. 
2004). The developing fetus will differentiate into a female in the absence of AMH, which allows 
the Müllerian duct to form into the upper vagina, uterus and oviduct (Hutson et al.1 981; van Rooij 
et al. 2005; Durlinger et al. 1999). Experiments that were conducted using AMH knock-out in 
mice brought to light the relationship of AMH and the ovaries whereby AMH inhibits growth of 
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resting primordial follicles (Broer et al. 2014; Durlinger et al. 2002; Durlinger et al. 1999). Current 
observations suggest that the absence of AMH leads to a higher rate of recruitment of primordial 
follicles resulting in exhaustion of the primordial follicle pool (Dewailly et al. 2014). 
AMH plasma levels are reflective of the growth of small, non-menstrual cycle dependent 
primordial follicles (Grynnerup et al. 2012; Weenen et al. 2004; Koskela and Tapanainen 2016). 
AMH is produced exclusively by the granulosa cells surrounding the immature oocytes in the intra-
follicular component producing high follicular fluid concentrations. During early childhood, there 
is an initial increase in AMH levels, which slowly declines thereafter until it is undetectable 
roughly 5 years before menopause (Broer et al. 2014). The decline is reflective of the diminishing 
stock of ovarian reserve. AMH does not accurately detect the quantity of remaining antral follicles 
or pool of primordial follicles in the ovaries but rather predicts the remaining length of a woman’s 
reproductive lifespan (Weenen et al. 2004; Grynnerup et al. 2012; Safdarian et al. 2012; Visser 
and Themmen 2014). For the last few years, AMH is thought to be the best endocrine marker for 
assessing the decline of ovarian reserve in healthy women relative to age (Broer et al. 2014).  
Infertility medicine uses AMH as part of diagnostic testing for patients. A strong 
correlation between AMH and antral follicle count (AFC) retrieved by trans-vaginal ultrasound of 
the ovaries was observed (de Vet et al. 2002). Furthermore, a strong correlation between AFC, 
AMH and age, and follicle stimulating hormone (FSH) was described in women undergoing IVF 
(van Rooij et al. 2005). There have been very few reports on the correlation of AMH and 
embryonic development, especially the rate of high quality blastocyst formation, for IVF patients. 
Of late, focus has been on AMH and its ability to predict implantation or pregnancy in IVF 
treatments versus rate of blastocyst formation. A meta-analysis of such focus had led to a 
conclusion that there is not a strong association of AMH and implantation potential (Tal et al. 
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2015). If rate of blastocysts formation can be accurately associated with serum AMH values, then 
patients with DOR or POF (poor prognosis group) can be counseled appropriately to calculate their 
rate of success using their own oocytes in IVF.  
 
1.3.3.2 Follicle Stimulating Hormone 
Follicle stimulating hormone (FSH) is a gonadotropin, a glycoprotein polypeptide hormone 
(Vegetti and Alagna 2006; Rinaldi and Selman 2016). The synthesis and secretion of this menstrual 
cycle-dependent hormone is controlled by the anterior pituitary gland. FSH regulates the 
development, growth, pubertal maturation and reproductive processes in the body (Smitz et al. 
2016). In the antral follicle the granulosa cells, the cells surrounding the oocytes, express FSH 
receptors. At the onset of the menstrual cycle a small number of antral follicles, usually 2-5mm in 
diameter are present in the ovaries (Pouwer 2015; Hodgen 1982). This group of follicles continues 
to grow in response to stimulation by FSH. This process is referred to as follicular recruitment. In 
the 1970s Brown introduced the concept of the FSH threshold on the basis of serum estrogen levels 
secreted by the developing follicle growth (van der Meer et al. 1994). According to this concept, 
increasing FSH concentrations should surpass a distinct level to initiate the final phase of follicular 
growth that is gonadotropin dependent. It has been hypothesized that follicles demonstrate varying 
degrees of sensitivity to FSH at the time of recruitment (Scheele and Schoemaker 1996). 
Therefore, the follicle with the highest sensitivity will benefit the most from increasing FSH levels 
and gain dominance over the remaining growing cohort of antral follicles in the IVF treatment, 
leading to maturity and ovulation (Visser and Themmen 2014). 
Infertility medicine uses basal FSH serum levels from blood drawn on menstrual cycle 
days 2-4, to determine ovarian responsiveness to gonadotropin treatment. Unfortunately, some 
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patients respond poorly to IVF stimulation and are referred to as “low” or “poor responders” (Vega 
et al. 2016; Oehninger 2011; Cohen et al. 2015). Women in menopause have high FSH levels, 
above 40 mIU/ml. This occurs because the pituitary continues to produce FSH in the absence of 
its “inhibitor”, estradiol, normally produced by maturing oocytes. FSH levels in DOR and POF 
patients will be elevated due to the diminishing reserve of oocytes remaining in their ovaries. The 
normal FSH value of reproductive women with good fertility potential is usually between 5-9 
mIU/ml (Barroso et al. 2001). Increasing values at baseline are suggestive of poor ovarian response 
to gonadotropin stimulation resulting in a decreased chance of live birth (Namwanje and Brown 
2016; Muasher et al. 1988). The focus for FSH in infertility has primarily been on response to 
stimulation and very limited information is available on basal FSH levels and their predictive value 
of the rate of high quality blastocyst formation in an IVF treatment. If a correlation is found, this 
would tremendously aid in counseling IVF patients with accurate success rates using their own 
oocytes.  
 
 In Vitro Fertilization 
Laboratories are currently practicing under the guidelines of the American Society of 
Reproductive Medicine (ASRM), which is a multidisciplinary organization dedicated to the 
advancement of the science and practice of reproductive medicine in the United Sates. A set of 
very strict criteria has led to uniformity across laboratories to maintain high standards in assisted 
reproductive technology (ART) laboratories. ART has been offered clinically in the US shortly 
after the birth of the first test tube baby, Louise Brown in 1978 (Steptoe 2015). Since then, there 
is a continued involvement of regulatory agencies such as the Food and Drug Administration 
(FDA), Occupational Safety and Health Administration (OSHA), Clinical Laboratory 
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Improvement Amendments (CLIA), College of American Pathologists (CAP), Joint Commission: 
Accreditation, Health Care Certification (JACHO), American Board of Bioanalysts (ABB), etc. 
This regulation had led to a well-established and accepted option of in vitro fertilization to the 
couples or even single persons that desire having a family and are unsuccessful in conceiving. 
Between years 2004 and 2013, the success rates of IVF treatments have only increased by roughly 
7% reflecting single live births by age group (“National ART Summary Report for 2013”). There 
have been advanced options offered to the ART laboratories such as the newer method of 
cryopreservation called vitrification versus the rate-cooling method of freezing blastocysts and 
cleavage stage embryos. Another advancement in IVF is the preimplantation genetic screening or 
diagnosis of cells biopsied from trophectoderm of blastocysts. This technique involves complete 
chromosomal screening of the embryos and allows for the selection of euploid embryos for transfer 
with the promise to increase the chances of pregnancy per IVF treatment up to 80% (Fiorentino et 
al. 2014; Rubio et al. 2003; Capalbo et al. 2014). 
Current methods in the field focus on increasing the success rate per IVF treatment by 
implementing an exclusion method for embryo selection. PGS excluded the aneuploid embryos 
from the patient cohort; vitrification excludes the poor quality embryos and offers a preservation 
solution for the high quality embryos. There has not been a solution proposed that will rescue 
poorly developing blastocysts from their unfortunate disposition of discard.  
 
 Embryo Culture 
In vitro fertilization uses the ability to culture embryos outside of the body in artificially 
constructed environments. The success of this procedure is reflected by the rate of live birth that 
is reported by laboratories. For a successful pregnancy to occur, it is essential for a laboratory to 
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grow high quality preimplantation embryos (Shahbazi et al. 2016; Gardner et al. 2005). Culture 
media have an impact on the quality of embryos generated in IVF treatments influencing 
implantation and pregnancy rates (Farquhar et al. 2013; Bungum, et al. 2002).  Several 
manufacturers2 offer FDA approved IVF culture media commercially available for purchase, each 
entailing a slightly different composition. Generally, all IVF laboratories maintain logs of quality 
control (QC) of their selected media, in which embryo culture is performed. This QC can include, 
but is not limited to: 
• pH levels at equilibration with specified CO2 levels (typically 6-7%) 
• Temperature at equilibrium (37˚C) 
• Rate of mouse embryo blastocyst formation with each lot/batch of media  
• Maintenance of a log of lot/batch numbers along with their initial use  
• End use and expiration dates  
 
1.3.5.1 Culture Media for IVF 
At the infancy of IVF, early 1990s, culture media in the United States consisted of a 
balanced salt solution, which included glucose and phosphate (Baltz 2012; Wang and Sauer 2006). 
Subsequently, more complex culture media formulations were introduced with addition of non-
essential amino, acids, chelators (EDTA), vitamins and antibiotics (Gardner et al. 1994; Van 
Blerkom et al. 2014). More recently sequential culture media were formulated after considering 
the changing metabolism of the embryo from fertilization to cleavage, then from cleavage to 
blastocyst (Gardner and Lane 1997; Barnett and Bavister 1996; de Los Santos et al. 2015). The 
cleavage stage embryo is characterized by  low levels for biosynthesis (Epstein and Smith 1973), 
                                                 
2 Manufacturers of IVF culture media in the United States that sell FDA approved media for human use include, but 
are not limited to: VitroLife, Life Global, Sage and Irvine Scientific.  
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low respiratory rates (Thompson et al. 1996; Niakan et al. 2012) and a low to limited ability and 
capacity to utilize glucose as an energy source (Gardner and Leese 1990; Gardner and Wale 2013; 
Wale and Gardner 2016). In contrast to cleavage stage embryos, post compacted embryos exhibit 
an increasing rate of biosynthesis and respiratory capacity along with their ability to utilize glucose 
as their energy source  (Wiley et al. 1986; Morbeck et al. 2017).  
The selected media for my studies, G-Series-TM media by VitroLife, is a sequential media 
that is FDA approved for the culture of human gametes and embryos. The first of the two-step 
media is the G-1 Plus, which is a medium for culture of embryos from the pronuclear stage to the 
day 3 cleavage stage. This is a bicarbonate buffered medium containing human serum albumin 
(HSA), hyaluronan and gentamicin as an antibacterial agent. The second of the two-step media is 
the G-2 Plus, which is a medium for culture of embryos from day 3 of embryonic development to 
the blastocyst stage. It also contains HSA, hyaluronan and gentamicin. Exact composition of media 
is found on the certificates of analysis, which are provided for each batch by the manufacturer and 
demonstrate little to no variability between batches (Appendix B, C).  
 
1.3.5.2 Equilibration pH 
It is essential to acquire the correct pH in culture media for gamete and embryo culture 
during IVF treatments (Steel and Conaghan 2008; Swain 2012; Swain et al. 2016). Culture media 
are routinely prepared as micro droplets of 40ul per drop in a Petri dish under culture oil (Swain 
et al. 2012). This design aids in limiting evaporation of the culture media and to maintain its 
osmolality. The range of pH for culture of human gametes and embryos is 7.2-7.4 (Steel and 
Conaghan 2008). The pH of the media is controlled by the concentration of carbon dioxide in the 
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incubation chamber. Carbon dioxide in the incubator is in equilibrium with dissolved carbon 
dioxide, carbonic acid, bicarbonate and carbonate:  
CO2 ⇌ H2CO3 ⇌ H+ + HCO-3 ⇌ 2H+ CO32- 
 The media at physiological pH is then approximated by the Henderson-Hasselbach 
equation (pH =pKa + log10([HCO-3]/[ CO2]) (Gwatkin 1993; Mioni and Mioni 2015). Relatively 
large changes in CO2 concentrations (+/- 0.2%) within an incubator cause only minor changes in 
pH (Gardner et al. 2005). It is very important to validate the media pH for a given media on a 
regular basis to ensure that it follows the recommendations for the specific media (Michelle Lane 
et al. 2008). This also ensures that the culture conditions are proper for embryos in any incubator. 
 
1.3.5.3 Partial Pressures of Oxygen and Carbon Dioxide 
Embryo development depends on a variety of factors, which include oxygen partial 
pressure during culture. Oxygen and carbon dioxide partial pressure have a crucial effect on 
embryo development. Gasses that are utilized by IVF laboratories are either 5-6% carbon dioxide 
and air (20.9% oxygen) or 5-6% carbon dioxide, 5% oxygen and 90% nitrogen (Waldenström et 
al. 2009; Nastri et al. 2016). The oxygen partial pressure in the oviduct and uterus for mammalian 
species has been determined to be in the range of 2-8% (Fischer and Bavister 1993; Archibald 
2003). Elevated and non-physiological oxygen concentrations could create unfavorable conditions 
in the substrate in the form of production of free oxygen radicals causing oxidative stress leading 
to the occurrence of high rate of fragmentation and arrest of embryos during development 
(Bedaiwy et al. 2004; Guérin et al. 2001; Peng et al. 2015). In the past there have been controversial 
results of oxygen stress and its impact on embryonic development. The ratio of oocytes collected 
per case compared to embryos viable on day 3 of culture has not shown to be significantly different 
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under ambient or low oxygen (5-6%) (Dumoulin et al. 1999; Peng et al. 2015; Swain 2015). 
However, the rate of blastocyst formation was negatively affected with lower percentage of 
embryos developing to blastocysts when culture was maintained in ambient oxygen concentration 
(Kelley and Gardner 2016; Dumoulin et al. 1999; Yang et al. 2016) . Not only were there 
improvements in blastocyst formation, but also improved pregnancy rates, implantation rates and 
birth rates were found from treatments whose culture was performed at low oxygen concentrations. 
It is well understood and accepted that the overall outcome of IVF treatments is improved with 
low oxygen stress during culture. However the narrow window of low stress has yet to be 
delineated. 
 
 Association/Dissociation of Sibling Trophoblast Cells 
Cell adhesion is maintained primarily by transmembrane proteins called cadherins (Mui et 
al. 2016; Simopoulou et al. 2014). Cadherin class of proteins comprise of hundreds of cadherins, 
however, E(epithelial)-cadherin, is the first of its class to be expressed in the mammalian embryo 
(Watson and Barcroft 2001; Zaidel-Bar 2013; Gilbert 2014). These proteins also play an important 
role in cell forming adherens junctions and bind cells together. Synthesized as polypeptides, 
cadherins undergo many post-translational modifications to ultimately form the proteins, in which 
cell to cell adhesion and recognition is functional (Harris and Tepass 2010; Mui et. al 2016). These 
polypeptides are approximately 750 amino acids long with a small transmembrane component and 
a bulk of the protein is extracellular. Cadherins are calcium (Ca2+) ion dependent in their 
functionality (Yap et al. 2015). Cell-to-cell adhesion is mediated by the extracellular component 
or domain of the protein, whereas the intracellular cytoplasmic tail integrates with other signaling 
and adaptor proteins referred to as cadherin adhesome (Zaidel-Bar 2013). This protein plays a 
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critical role in morphogenesis and homeostasis and has 3 major functions in animals (Basilicata et 
al. 2016; Zartman et al. 2009; Priya and Yap 2015). First, cadherins provides adhesion tension, 
which lowers interfacial tension at the cell to cell contact. Second, they signal to the actomyosin 
cytoskeleton to reduce cortex tension, which reduces interfacial tension at contact. Third, cadherins 
stabilizes the contact by resisting mechanical forces that work against this contact by force. 
Cadherins are involved in determining cell shape and position of different species. For example, 
in zebra fish and Caenorhabditis elegans, cadherins are implicated in germ cell positioning (Babb 
et al. 2001; Callaci et al. 2015). In Drosophila they are involved in the oocyte positioning within 
the oocyte chamber and in Drosophila and C. elegans, they are involved in the epithelial folding 
and mesoderm/endoderm cell internalization (Maître and Heisenberg 2013; Zartman et al. 2009). 
For the purposes of cell culture, media are kept close to physiological conditions. 
Removing calcium and magnesium ions from cells or tissue would weaken the cadherins in cell 
bonds and cause cell-to-cell dissociation (Ohnuma et al. 2014; Heng et al. 2009). This exact 
technique is the underlying mechanism for the out-dated method of embryo biopsies in human 
IVF. In the past, embryos were biopsied on IVF treatment day 3 at the cleavage stage of 
development. The embryo was then placed in a calcium and magnesium-free solution and allowed 
to equilibrate for 10-15 minutes. A hole was then created in the zona pellucida of the embryo and 
a single cell was pulled away using micro-tools under an inverted microscope (Olympus IX70) 
(figure 1.5). The weakening of the cells, in the absence of calcium and magnesium allowed the 
technician to remove this “biopsy” or cell without causing damage to the remaining embryo. Once 
the biopsy was removed, the embryo would be placed back in the normal culture media and the 
cell bonds would re-associate (Łukaszuk et al. 2015; Heng et al. 2009; Kawakami et al. 2006). The 
embryo would continue its cell divisions as normal. This technique is no longer used due to the 
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limitations of biopsy3 and removal of only one blastomere versus 5-6 trophoblast cells biopsied at 
the blastocyst stage. This is due to the availability of more cells at a later stage leading to a more 
robust preimplantation genetic screening analysis (discussed in Chapter 4). Many of the 
commercial cell media companies offer FDA approved calcium and magnesium free solutions for 
this specific purpose. This technique has not been applied to the current TE biopsy of the day 5 
embryo due to the availability of the laser4 lens, which emits pulses for ablation of the cells to 
perform a biopsy.  
 
 Examples of Chimeric Growth 
The basis of the proposed sibling trophoblast study is the theory that the trophectoderm 
cells are differentiated and are programmed to support the ICM regardless of mosaic or chimeric 
state. Many experiments using mapping techniques have been performed to determine the ultimate 
fate of a single cell at the embryonic stage to the tissues and organs that arise from it at an adult 
stage. Most model organisms have been mapped – e.g. the zebra fish and C.elegans. Viable 
chimeras produced from mouse embryos have been reported (Solter 2010; Hizanidis et al. 2016). 
In this case, cleavage embryos were removed from their zona pellucida and placed together in 
continued culture. The resulting embryos were an integration of the two cell lines, chimeric. A 
chimera is an organism with cells from two genetically different zygotes. These embryos were 
transplanted to the uterus of the foster mother mouse and live births were reported. The adult 
chimeras were then mated with normal mice and were proven to have uncompromised fertility. No 
adverse events were reported in development.  
                                                 
3 Day 3 blastomere biopsy and its limitations are beyond the scope of this project. (For review, see Magli et al. 2016) 
4. The Saturn Laser Lens is used for all biopsy procedures in the proposed studies. 1480nm / 400mW solid state diode 
laser. Pulse length range 0.005-2.0ms / 5-2000µs. http://www.research-instruments.com/saturn-5/ 
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Figure 1.5. Day 3 embryo biopsy.  On day 3 of embryo development, an embryo is between 6 and 
8 cells (A). The zona pellucida is ablated and a single cell is removed from the embryo using 
micromanipulators (B, C). This single cell serves as a “biopsy” and is then sent for preimplantation 
genetic screening (D).  Courtesy: Dallas IVF  
 
Attempts have been made to knock out a gene of interest in a mice strain and constructed 
chimeras (Cheatham et al. 2009). The chimeras were produced by fusing the embryonic cells of 
the two mice strains to construct a mouse with the desired knock out (Cheatham et al. 2009) . Are 
chimera’s possible in humans? There is even evidence that human embryos can form chimeras 
(Benirschke et al. 1972; Ali et al. 2017; Bens et al. 2017). Some individuals have two genetically 
different cell types (XX and XY) with in the same body. Each with its own set of genetically 
defined characteristics. Usually individuals that have this complete fusion of embryonic cells that 




male and female. Then there are other cases such as monozygotic twinning, particularly cases that 
develops into one chorion (separating fetuses) and one placenta (shared between the two fetuses). 
Pregnancies that comprise of twins sharing the same placenta have concerns that are similar to the 
ones in this research such as same blood supply shared between two fetuses. There are reported 
live births of twin gestations that have lived healthy lives, have full reproductive potential and 
have not been developmentally impacted (Bui et al. 2015; Gielen et al. 2006). 
In an effort to reduce the risks associated with transferring a chimeric or abnormal embryo, 
IVF laboratories in the country offer pre-implantation genetic screening of embryos created in IVF 
treatments. The ability to test the genetic makeup of an embryo reduces the likelihood of an 
abnormal pregnancy, miscarriage or no pregnancy. This testing is now discussed. 
 
 Preimplantation Genetic Screening 
Preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) 
have been used in IVF to detect unbalanced chromosome copy numbers or single gene disorders 
in embryos (Zhu et al. 2014; Capalbo et al. 2014; Sermon et al. 2016; Staessen et al. 2008). There 
are three widely used methods of testing offered to patients undergoing IVF, which include array 
comparative genomic hybridization (aCGH), small nucleotide polymorphism (SNP) array, and 
next generation sequencing (NGS). Chapter 4 study focuses on the differences in the pregnancy 
rates achieved when embryos were transferred using the various methods of screening or 
diagnosis. 
 
1.3.8.1 Array Comparative Genomic Hybridization 
Often referred to as a microarray or array CGH, this test can detect small changes in the 
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chromosomes such as micro-deletions or duplications (Valli et al. 2015; Harper and Harton 2010; 
Kotdawala et al. 2016). The micro-chip based array exploits the ability of the DNA molecule to 
bind specifically to another DNA molecule. The microarray comprises of tens of thousands of 
short sequences of DNA called probes that are arranged in a precise grid on a glass slide referred 
to as a “chip”. The biopsy cell samples from the embryos are lysed to retrieve the DNA, which is 
amplified and then digested into short fragments (Rubio et al. 2013). These fragments are then 
labeled with a colored fluorescent dye. The reference DNA or control, with no genetic anomalies 
is then labeled with a different color fluorescent dye. The test and control samples are mixed 
together and hybridized to the probes on the microarray chip. A scanner then measures the amount 
of the two different dyes on each probe. Ratios of the dyes are calculated by analytical software to 
determine if the test sample has the correct copy number of chromosomes. Duplications and 
deletions of whole chromosomes or large portions of chromosomes can be detected by this method 
(Adler et al. 2014; Kotdawala et al. 2016; Fragouli and Wells 2012). The limitations of this method 
are that aCGH cannot detect uniparental disomy, mosaic cell lines, small segmental deletions or 
duplication or trisomy across all chromosomes (Liu et al. 2011; Handyside et al. 2012; Handyside 
2013).  
 
1.3.8.2 Small Nucleotide Polymorphism Microarray 
Small nucleotide polymorphisms are small areas of the genome within, which a single 
nucleotide in a sequence varies within a population. SNP arrays detect uniparental disomy by 
comparing the variable regions of DNA if parental blood or buccal samples are provided (Ahmad 
and Iqbal 2012). A typical array will have hundreds of thousands of SNPs to access using validated 
software that can determine how many of each chromosome number was inherited by the embryo 
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from each gamete donor (Schroeder et al. 2013; Zhu et al. 2014; Adams et al. 2012). This is 
performed by analyzing both quantitative data and analyzing the expected combination of inherited 
chromosomes and comparing them with the actual outcome (Harper and Harton 2010).  After 
whole genome amplification is performed on embryo biopsied cells, the DNA is labeled with red 
and green fluorescent molecules with one version of the SNP in red and the other in green 
(Dahdouh et al. 2015). The DNA is then assessed for intensity of the fluorescent signals as well as 
the SNP calls. This is compared with the control samples (DNA of the gamete donors) by a 
validated software, which establishes diagnosis of disease and confirmation of inheritance of 
chromosomes and copy chromosomal number (Harper et al. 2010). SNP arrays offer options that 
are not available with aCGH. For example, in addition to detection of uniparental disomy, SNP 
arrays can perform simultaneous testing of single gene disorders along with complete 
chromosomal screening (Singh et al. 2015; Li et al. 2014). Due to these added benefits, this method 
of screening and diagnosis has been utilized more often for IVF (Fragouli and Wells 2012). 
 
1.3.8.3 Next Generation Sequencing 
Next generation sequencing (NGS) is a new emerging technology that is yet to be validated 
for clinical use (Muzzey et al. 2015; Visser et al. 2017). It is a high throughput based non-Sanger 
sequencing technology that allows sequencing of increased number of samples simultaneously 
(Meller 2015). NGS offers enhanced detection of partial or segmental aneuploidies, detection of 
mosaicism in multicellular samples and the potential of automation of sequencing library to reduce 




1.4 Raising the Bar for IVF Treatments 
The Society of Assisted Reproductive Technology and the CDC reports diminished ovarian 
reserve as the second leading diagnosis for IVF accounting for 31% of ~232,000 IVF treatments 
in the United States in 2015 (“2015 ART National Summary Report” 2017). This diagnosis is 
accompanied by challenges of poor prognosis, as previously discussed. IVF treatments are 
emotionally and financially costly and can lead to added stress for patients presenting with DOR. 
It is therefore, my aim to understand and define culture conditions, stimulation treatment effects 
and embryo selection methods, which can optimize success for patients with diminished ovarian 
reserve and broaden the scope of the field by providing an experimental inclusion method for 
poorly developed blastocysts, which may increase rate of high quality blastocysts development 
leading to overall increase in treatment success.  
The next chapters outline and investigate methods for optimization of IVF.  Chapter 2 
discusses the statistical methodologies applied to chapters 3-6 with concentration on the power of 
analysis with interactions. Chapter 3 explores embryonic adaptability in the form of integration of 
sibling graft cells in the mouse to aid in blastocyst growth built on the foundation of chimeric 
organismal development. Chapter 4 focuses on the more suitable and constructive approach to pre-
implantation genetic screening methodologies and limitations associated with each technique for 
the most favorable application for infertile patients. Chapter 5 concentrates on the power of 
diagnostic factors such as basal follicle stimulating hormone and anti-müllerian hormone 
combined with actionable variables during an IVF treatment cycle such as gonadotropin dose for 
ovarian stimulation and day-of-trigger to build a prediction model for use with IVF treatments 
improving blastocyst development. Chapter 6 investigates the fundamental, yet paramount 
principals of medium pH, pCO2 and pO2 to discern association of subtle batch-to-batch variability 
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and their implications on developing embryos. Thus, you are presented with some of the most 
leading factors associated with human IVF focusing on blastocyst development, especially for 
DOR and POF patients. Chapter 7 integrates findings to show how individualized and tailored 
approach to IVF can maximize blastocysts developmental success and lessen the financial and 




CRITIQUE AND EXPLANATION OF STATISTICAL METHODS 
2.1 Introduction 
Conventional methods to analyze scientific experimental data have been successfully and 
effectively used for many years. Examples of these methods include analysis of variance 
(ANOVA) and Chi-square tests. These methods are a part of statistical modeling, which formalizes 
relationships between variables in the form of mathematical equations (Khuri 1999; Rutherford 
2011). ANOVAs (one, two and three-way) are strong analyses that can identify variability in 
observations. They are effective for a variety of data-sets that have 1-3 variables, providing 
significance values to indicate importance. While this conventional method provides a strong 
power of analysis, its application and effectiveness in large data sets comprising bioinformatics is 
limited.  
 
 ANOVA Analysis 
Often, researches apply one-way ANOVA for a given factor (primary) for each level of the 
other factor (secondary), repeatedly. This strategy suggests that their interest lies in the secondary 
factor, therefore implying that one-way ANOVA is the appropriate methodology. As an example, 
if patient age was the primary factor and pregnancy was the outcome, one-way ANOVA would 
likely find a significant relationship. However, embedded variation within age such as type of 
infertility (i.e., diminished ovarian reserve, endometriosis, hypogonadism, hypothyroidism, male-
factor, etc.) would be unaccounted for. The multiple interactions of diagnosis on patient age are 
not detectable by the one-way ANOVA due to its limitations in identifying weights of interactions 
between explanatory variables on final outcome.   
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Taking critiques of statistical methodology a step further, application of two-way ANOVA 
analysis requires the experimental data to have the same number of combinations of observations 
among the variables of interest and the outcome variable. If this combination is out of balance, the 
analysis is then conducted without interactions. This model provides main effects (no-interactions) 
to determine effect of one factor from that of another. The prior, interaction model, includes the 
relationship between variables and thus accounts for interactions (Kim 2014). As an example, if 
the diagnosis of diminished ovarian reserve was the primary factor with number of fertilized 
oocytes in treatment as the secondary factor and outcome is observed as pregnancy, the primary 
factor consists of variation within the population, i.e. age of patient. The lack of accountability of 
interaction analysis of variables within a study can easily result in unexpected and surprising 
results. In a case like this, researches often choose to lump patients into age categories like 20-34 
years, 35-37 years, 38-40 years, etc. as is reported by SART for in vitro fertilization in the United 
States (see Chapter 1). Once grouped, this data set can be analyzed in groups, including a couple 
of variables in each analysis and output is often compared across the age categories. As a 
consequence, lumping of maternal age within groups to create categories is misleading because it 
determines the slope of the curve within a narrow window of age, expressing the data as a linear 
model. If maternal age was analyzed as a continuous variable compared to categorical lumping, 
the slope is drastically different for pregnancy outcome resulting in a non-linear and parabolic 
curve, consequently changing interpretation of the final analysis. 
When more than three variables are involved per observation, which is emblematic of 
bioinformatics study data, the analysis becomes overwhelmingly complex. Some scientists may 
split the data in parts to perform multiple ANOVAs as their choice method of analysis. For 
example, a dataset, which has six variables (A-F) may be analyzed in 3 runs: variables A and B 
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against outcome, then variables C and D against outcome, and finally variables E and F against 
outcome. A post-hoc multiple comparisons may be implemented as if the three independent 
analyses were performed as one set. Selecting certain variables by choice per treatment to include 
in an ANOVA analysis in groups compared to all variables against outcome discriminated in one 
analysis results in a loss of interactions among variables. This masks critical information on the 
weighted influence of variables on outcome or each other. The results are consequently mis-
interpreted giving significance to a variable that is possibly only significant because it was coupled 
with a highly insignificant variable in the analysis which otherwise, is truly insignificant in the 
presence of another variable with greater weight on outcome. Alternately, significance due to 
combined effect of variables can be missed if the grouping has not included interacting variables.  
Specifically in my dataset for Chapter 6, a total of 16 variables were included per 
observation. As is discovered by the reader, the focus of the study was to understand outcome in 
the form of blastocyst development rate related to culture conditions to include pH, partial 
pressures of carbon dioxide and oxygen. By graphically representing the output readings of pCO2 
against pH by medium type the inverse relationship of carbon dioxide and pH is depicted (figure 
2.1). Outliers in the data set are plotted in this figure and the majority of the data readings were 
consistent as represented by batch number. The top panel shows 2 batches plotted for primary 
culture medium G1TM Plus (VitroLife) (figure 2.1A) and lower panel shows 3 batches for 
secondary culture medium G2TM Plus (VitroLife) (figure 2.1B).  
Of critical importance in justifying the analyses used in this thesis, performing ANOVA 
on these two variables may or may not show significance between batch and readings. However, 
the results of this analysis are invalid since the interactions between incubator number, incubator 
temperature, age of female producing oocytes, infertility factor associated with the patient’s 
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oocytes and some of the other variables directly influencing final outcome have not been included. 
As documentetd in Chapter 6, an effect on outcome was found, however, it was not due to batch-
to-batch variation, as I conclude by evaluating figure 2.1. Instead, I found pCO2 and pO2 to have 
a stage dependent and patient diagnosis dependent effect on final outcome. ANOVA would be 
unsuccessful in identification of this critical finding. 
 
Figure 2.1. Comparison of pH and pCO2 by medium. G1 Plus is the primary medium supporting 
embryonic development to cleavage stage, where-as G2 Plus supports embryonic development 
from cleavage stage to blastocyst stage. A plot of two batches for G1 Plus and three batches of G2 
Plus demonstrates the inverse relationship of pH and pCO2 and regression lines for observations 
are plotted. Regression lines are plotted and the slopes of the lines are influenced by outliers. This 
subtle difference can alter the slope of the curve and identify this as significant. The differences in 
batch characteristics, when examined without other variables in the study, incorrectly analyze 
significance due to missing interactions. This form of analysis for a large bioinformatics datasets 
results in false positive findings. 
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 Chi-Square Analysis and Fisher’s Exact Test 
Analysis of raw data in chapter 4 (Pre-implantation genetic screening study) for 
comparison of pregnancy and implantation outcomes to reference group was made through the 
Pearson’s chi-square and Fisher’s exact test (Ugoni and Walker 1995), initially. Results of P < 
0.05 were considered significant. Pearson’s chi-square analysis (Khuri 1999; Pandis 2016) 
determined that the clinical pregnancy rates of the reference and treatment groups in the outcome 
for single embryo transfer (SET), double embryo transfer (DET) and overall clinical pregnancy 
rate categories were not statistically different (table 2.1). Individuals in all treatment groups had a 
mean female age that was not different (P=0.073) (determined using one-way ANOVA) (Kim 
2014). The mean female age in the reference group was significantly different than the treatment 
groups (P<0.001) (determined using ANOVA), consisting of a younger patient population (group 
A was 32.4 ±3.7 years, B was 35.5 ± 4.1 years, group C was 35.1 ± 4.4 years  and group D was 
36.4 ± 3.5 years). 
Table 2.1. Comparison of pregnancy and implantation outcomes to reference group 
 Group A Group B  Group C  Group D  
Parameter No PGS aCGH P value NGS 
P 
value SNP array 
P 
value 
# of treatments with SET 142 41 -- 37 -- 49 -- 
# of treatments with DET 81 15 -- 13 -- 24 -- 
Clinical pregnancy rate with SET % (n) 59.8% (85) 68.3% (28) 0.448a 51.4% (19) 0.455 a 67.3% (33) 0.448 a 
Clinical pregnancy rate with DET % (n) 66.7% (54) 86.7% (13) 0.219b 53.8% (7) 0.369 b 70.8% (17) 0.893 a 
Overall clinical pregnancy rate % (n) 62.3% (139) 73.2%  (41) 0.172a 52.0% (26) 0.234 a 68.5% (50) 0.418 a 
Overall implantation rate % (n) 49.5% (151) 63.4% (45) 0.051 a 50.8% (32) 0.981 a 56.7% (55) 0.276 a 
Overall ongoing pregnancy rate % (n) 55.6 %  (124) 66.1% (37) 0.205a 46.0% (23) 0.205 a 60.3% (44) 0.060 a 
Overall miscarriage rate % (n) 10.7% (15) 9.8% (4) 0.938 a 11.5% (3) 0.827 a 12% (6) 1.000 a 
SET single embryo transfer, DET double embryo transfer 
aP values determined using Chi-square analysis. 
bP values determined using Fisher’s Exact test. 
The same parameters outlined in table 2.1 were re-analyzed for significance using the 
Pearson’s chi-square test to compare the treatments to each other. Surprisingly, no significance 
occurred in the clinical pregnancy rate across all three categories (table 2.2). Although the overall 
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chemical pregnancy and implantation rate were the highest in group B (aCGH) per embryo 
transferred (figure 2.1) there was no significant difference in outcomes across treatments in this 
form of analysis. Due to the unexpected lack of significant differences in outcomes between 
treatments, the data were re-evaluated using a more powerful analytical method factoring in the 
interactions of the variables (Chapter 4). The random forest analysis was used in this chapter and 
interactions that weighed heavily on outcome were identified with the highest weighted variable 
being female age. This interaction and others were missed using Chi-square and fisher’s exact 
analysis on this type of data. The results were incorrect and significance between treatments and 
their dependence of female age was not identified until the application of random forest. 
Table 2.2. Comparison of pregnancy and implantation outcomes amongst screening groups 
 Group B Group C Group D  
Parameter aCGH NGS SNP array P value 
# of treatments with SET 41 37 49 -- 
# of treatments with DET 15 13 24 -- 
Clinical pregnancy rate with SET % (n) 68.3% (28) 51.4% (19) 67.3% (33) 0.229 a 
Clinical pregnancy rate with DET % (n) 86.7% (13) 53.8% (7) 70.8% (17) 0.161 a 
Overall clinical pregnancy rate % (n) 73.2%  (41) 52.0% (26) 68.5% (50) 0.055 a 
Overall implantation rate % (n) 63.4% (45) 50.8% (32) 56.7% (55) 0.337 a 
Overall ongoing pregnancy rate % (n) 66.1% (37) 46.0% (23) 60.3% (44) 0.878 a 
Overall miscarriage rate % (n) 9.8% (4) 11.5% (3) 12% (6) 0.926 a 
SET single embryo transfer, DET double embryo transfer 
aP values determined using Chi-square analysis. 
Against this backdrop, I explored the even stronger power of analysis that is offered by 
machine learning, namely so-called “predictive modeling”. Machine learning roots from computer 
science and artificial intelligence with systems that learn from experimental data compared to 
analysis based explicitly on programmed instructions (Baştanlar and Ozuysal 2014; Deo 2015).  A 
relatively new field, machine learning provides an impressive processing power of computers 
programmed to make successful predictions given the complexity of the data. For example, with 
the World Wide Web at our fingertips, the public uses search engines like Google to perform 
38 
queries on topics of interest. Sites such as this provide tools to filter results, which can be billions 
of web pages. This filtration tool is used to sift through the results to find patterns most relevant to 
the query and provide a condensed list of results that are most applicable.  
This type of process has evolved through fields like computer science and physics and are 
often referred to as “machine learning”, “artificial intelligence”, “data mining”, “predictive 
analysis”, etc. (Kuhn and Johnson 2013). This form of artificial intelligence is programmed to 
“learn” as the characteristics of the data set change. For example, we rely heavily on our email 
filters to accurately identify certain types of emails as spam. As the user selects emails in the inbox 
as spam, the algorithm learns from patterns within emails that characterize them as spam for the 
user. Ultimately, the user is satisfied with the filtering capability of the software and checks the 
spam folder less frequently.  
Understanding the power of analysis that predictive modeling provides for datasets 
involving 10 or more variables I chose Random Forest and Evtree analysis methods for my studies. 
I now discuss the methodologies involving each of the analyses. 
 
2.2 Statistical Methods Employed in This Thesis 
 Random Forest Analysis 
The Random Forest algorithm was created by Breiman (2001). The basic unit and 
foundation of this and the Evtree (discussed next) is a “tree” with one main “node” or the trunk 
from which all possible combinations stem. This tree then splits into smaller branches with the 
split at each branch referred to as a “node” and the “leaves” of each branch represent a 
homogeneous sub-group (figure 2.2). This tree-based regression approach creates thousands of 
trees with datasets. Each is unique, slightly different from the others created in the analysis.  
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Random forests randomly selects predictions at each split starting with the most weighted variable 
at the top creating splits called “nodes”. Each node then produces two subgroups called “leaves”. 
The algorithm learns and tunes using the similarities prevalent in each tree generated and produces 
a final tree with split rules. The split rules are created by maximally discriminating between the 
two subgroups (leaves) providing the split (node), however maintaining the most homogeneity 
within each of the independent subgroups. The variables are weighted for importance using the 
mean decrease Gini index, a coefficient to measure the contribution of each variables to the 
homogeneity of the nodes and leaves in the final random forest model (Menze et al. 2009; 
Handyside et al. 2012). For each split the Gini index coefficient of the resulting node is calculated 
and a comparison is made to the original node ultimately producing a weight of each variable in 
the final decision tree or predictive model.  
The predictive model uses multinomial logistic regression, which can predict the 
categorical membership of a dependent variable based on multiple independent variables 
(Starkweather and Moske 2011). This method that utilizes boot strap re-sampling, by which the 
algorithm includes 70% of observations in the dataset to compose the final tree labeled as “in bag” 
and the remaining 30% as “out of bag” observations are fitted through the final tree for accuracy 
of the prediction. This approach is used to compose the final tree minimizing over fitting the model 
(Breiman 2001; Gromski et al. 2014). The random forest algorithm perturbs sample through re-
sampling, dropping the variable of lowest importance. All interactions that influence outcome are 
accounted for within the iterations conducted by the analysis. The algorithm has a tuning parameter 
call the mtry, which is recommend as one-third of the number of predictors (Breiman 2001). Since 
the analysis is intensive, the number of randomly selected predictors k, should also be considered. 
The algorithm tunes mtry by the value of k to maximally produce optimal results that do not over 
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fit the data. The mathematical interpretation of the analysis is explained by Breiman (2001), 
naming random forests as more efficient than other bagging tree analysis methods since it requires 
fewer variables to predict each split in the tree building process. This method, on the other hand 
requires more trees, however, the combination of parallel processing gives the random forests 
higher efficiency computationally than other methods involving boosting (Kuhn and Johnson 
2013). 
Although random forests provide a strong and robust analysis, other approaches provide 
alternate, and powerful, computations which can be conducted in a shorter amount of time. I now 
discuss one such method known as the Evtree. 
 
 Evtree Analysis 
Evtree, short for evolutionary tree, analysis is an alternative method to compute predictive 
modeling based on a genetic and global optimization method  (Grubinger et al., 2014). Inspired by 
Darwinian evolution, the algorithm employs concepts such as inheritance, natural selection and 
mutation to calculate a decision tree. Population based trees are simultaneously fitted by variation 
operators called mutation and crossover, which merges various solutions. Ultimately, the 
“survivor” selection is an evolutionary process, in which the quality of the population is increased 
over time (Eiben and Smith 2007). This analysis uses Bayesian Information Criterion (BIC) to fit 
the survivor model (Volinsky and Raftery 2000). Initialization of the analysis is conducted by a 
valid, randomly generated root node. From this point, iterations are only selected once to be altered 
by the variation operators to give rise to the parent nodes. The evaluation function of the algorithm 
formulates, through statistical and mathematical computations, the requirements for the population 
adaption. In this approach each parent solution competes for its place in the population with the 
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offspring. The split rules are determined for the offspring population to be discriminate from the 
parent population, however mutated from the sibling population in terms of nodes on the tree. 
Finally, termination of the analysis is reached when the top 5% of the generated trees are stabilized 
for a minimum of 100 iterations. 
 
Figure 2.2. Decision tree. This figure is representative of a predictive modeling decision tree. The 
gray boxes indicate the terminology associated with the various parts of the model. 
 
Evtree does not perturb variables due the evolutionary nature of the analysis. It does not 
use bootstrap re-sampling or cross validation like random forests. Instead the Evtree package in R 
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software, implements an evolutionary based algorithm used to learn the classification of global 
optimality of a dataset.  
 
 Receiver Operating Characteristic Curve 
Receiver operating characteristic curves are a tool  used for the evaluation of classifiers in 
applications utilizing datasets for bioinformatics (Robin et al. 2011; Hajian-Tilaki 2013). This 
curve is commonly used in predictive modeling analyses, such as random forest and Evtree, for 
supplemental verification of the accuracy of the prediction model. Commonly referred to as the 
ROC curve, this graphical plot illustrates the strength of the diagnostic ability of a binary 
classification (positive/negative) system as the threshold of this system’s discrimination varies 
(Powers 2011) . The curve is created by plotting the true positive rate against the false positive rate 
of a model over varying thresholds. The true positive rate is known as sensitivity or the probability 
of detection in machine learning (Froud and Abel 2014). Similarly, the false positive rate is known 
as specificity and can be calculated (1-specificity). In a prediction model using the probability 
distributions of detection rate and specificity, the ROC curve is generated by plotting the area 
under the curve as the probability of distribution up to the discrimination threshold of the detection 
probability on the x-axis and the distribution function of sensitivity on the y-axis. 
The ROC curve maps output in classes. In a binary classification system, there are two 
outcomes: positive and negative. If the prediction model predicts an actual positive value as 
positive it is plotted in the top left quadrant. However, actual negative observations which are 
predicted as positive by the model are plotted in the top right quadrant and are false positive also 
known as type I errors.  Actual positive values predicted as negative are plotted in the bottom left 
quadrant, a type II error. Finally, the bottom right quadrant represents actual negative values 
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predicted to be negative by the model. Figure 2.3 is an overlap of the binary classification table 
with a ROC curve. The “area under the curve” (AUC) is referred to as the trapezoidal area under 
the curve to the 45˚ diagonal line stretching from the bottom left (100% specificity, 0% sensitivity) 
to the top right (0% specificity, 100% sensitivity). The further in the top left quadrant the ROC 
curve stretches, the stronger the predictability power of the model resulting in higher chances of 
the model’s accuracy when it predicts an actual positive condition as positive (Kuhn and Johnson 
2013). An AUC of 1 represents a perfect test with 100% predictive accuracy, while an AUC of 0.5 
represents a poor test, in which the prediction accuracy is no better than chance. AUC of 0.6 
represents a model that predicts 10% greater success than chance and is the lowest measure of an 
acceptable prediction model. 
 
Figure 2.3. Receiver operating characteristic (ROC) curve. A sample curve is superimposed on a 
prediction table. The 45˚ line demonstrates the role of chance for any predicted condition to result 
in the true condition. The gray areas of the curve represent confidence intervals where the lowest 
predictive success and the highest predictive success of the model can be calculated. 
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The ROC curve is an analysis performed on the accuracy of the entire and final prediction 
model, representing the accuracy of any final node/leaf on the tree. ROC curves are calculated to 
consider all factors acting simultaneously and instantaneously on outcome as the discrimination 
threshold varies of the final prediction model. Therefore, ROC curves are a useful tool in 
understanding the accuracy of prediction models. 
 
 Confidence Intervals-95%: Measure of Effect Size 
Confidence intervals (CI) are an important measure of certainty and they determine the 
accuracy of the effect size of treatment to determine the model’s practical significance (Banjanovic 
and Osborne 2016; Davison and Hinkley 1997). Effect size of a treatment in a predictive model 
will provide the magnitude of the power of a finding and the CI provides the reliability potential 
of a decision in the predictive model. I used 95% confidence intervals for all analysis of prediction 
models in my studies using a function called ‘boot.ci’ in R software, where CI were calculated. 
This function produces statistics with re-sampling (Canty and Ripley 2017). Larger re-sampling 
will ensure higher accuracy of the CI. For example, figure 2.3 is a computer code that was prepared 
for analysis performed in chapter 4 (PGS comparison study) where one of the goals was to 
determine if treatment with PGS (Group B, C, or D) was more beneficial than no treatment (group 
A, reference). The re-sampling size was set to 5000 iterations. The resulting 95% CI was reported 
as: 0.6358 - 0.7706. A lower limit of CI at 0.5000 would indicate that the results are no better than 
chance, (50%) accuracy. In this example, the lower limit of CI (0.6358) indicates that the decision 
of the predictive model is 13% greater success than chance alone at its lowest accuracy. The higher 
limit of CI (0.7706) indicates that the decision of the predictive model is 27% greater success than 
chance alone at its highest accuracy. 
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Confidence intervals (CI), being an analysis on effect size, generally becomes narrower as 
the sample size increases. Data with smaller sample sizes usually will have large variability in 
results compared to larger sample size data. CI will result in a true value of the data correlation 
when sample sizes are larger. A narrower range of CI will indicate a higher reproducibility 
compared to a wider range. 
 
Figure 2.4. Confidence intervals-95%, boot.ci. This is a sample code that was written for 
confidence interval analysis performed in chapter 4 to determine the effect size of treatment group 
B (aCGH) against group A (reference). The software package “boot.ci” was programmed to run 
5000 replicated for the determination of the final CI. For this analysis, the Area under the curve 
was 0.7041 with a 95% confidence of 0.6358-0.7706 accompanied by a ROC curve.  
 
With careful consideration of applicable statistical methodologies, I used evolutionary tree 
(Evtree) predictive modeling analysis for the data analysis in Chapters 3, 5 and 6. I used random 
forest predictive modeling analysis for data analysis in Chapter 4. All predictive models were 
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accompanied by ROC curves to determine the overall accuracy of the model along with 95% CI 
to indicate the effect size of treatment, taking both specificity and sensitivity into account.   
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CHAPTER 3 
GRAFT TRANSFER-EMBRYONIC STEM CELLS (GT-ESC) IN SIBLINGS BLASTOCYSTS 
OF THE MOUSE, Mus musculus 
3.1 Introduction 
The first binary cell differentiation in mammalian embryos occurs when their totipotent 
cells differentiate into either an inner cell mass (ICM) or trophectoderm (TE). This critical action 
results from the expression of various transcriptional factors activating genes specific to either TE 
cells or ICM (Ralston and Rossant 2010). Prior to blastulation, one of the most crucial events in 
mammalian embryonic development is compaction. Mouse blastomeres, following the third 
cleavage, form a compact ball of cells referred to as a morula (Kelley and Gardner 2017). Each 
morula consists of inner cells surrounded by a large group of external cells. The compaction is 
promoted in part by the expression of cell adhesion proteins such as E-Cadherin, which when 
expressed, form tight junctions between the outer cells of the morula (Li et al. 2009; Maître and 
Heisenberg 2013; Toh et al. 2015). Most of the external cells become the TE; whereas the inner 
cells become the ICM. As the embryonic cells continue to develop, blastulation positions the ICM 
to one side of the TE ring. Upon blastulation, TE cells are bound via E-Cadherins (Alikani 2005). 
This trans-membrane, calcium dependent, glycoprotein of 120-kDa interacts with the cytoskeleton 
through catenin proteins (Maître and Heisenberg 2013) enabling a successful adhesion and 
integration of cells (see Chapter 1). E-Cadherin also regulates epithelial junction formation while 
associating with catenin proteins (Zaidel-Bar 2013; Palacios et al. 2005; Fleming et al. 2001). The 
ICM gives rise to the fetus whereas, the trophectoderm cells give rise to extra-embryonic structures 
such as the placenta, umbilical cord and the tissues of the chorion, which aid in delivery of oxygen 
and nutrients from mother to the developing fetus (Natale et al. 2017; Sagrillo-Fagundes et al. 
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2016). The formation of the ICM is, of course, as crucial to live birth as the proper formation of 
the TE cells. Both cell types are therefore, assessed in in vitro fertilization (IVF) procedures.  
In vitro fertilization is the process, which allows for multiple oocytes from a genetic mother 
to be inseminated during one treatment creating multiple blastocysts. Blastocysts develop 
simultaneously in culture, of which one well developed blastocyst may be transferred to the 
mother’s uterus for a presumable pregnancy. The remaining high quality blastocysts may be 
cryopreserved for future potential pregnancy attempts. It is on the 5th day of human embryo 
development when blastocysts are fully formed and observed in vitro and are morphologically 
assessed. TE and ICM cells differentiate and can be distinguished at this time in development. 
High quality blastocysts determined to be suitable for uterine transfer or cryopreservation exhibit 
a well formed TE and ICM group of cells. There are however, blastocysts which develop an 
exiguous number of TE cells even if the ICM is well developed. Such blastocysts are destined for 
discard due to low survivability from vitrification and warming (Zhu et al. 2014; Veleva et al. 
2013).  
To optimize the number of high quality blastocysts produced from an IVF treatment, I have 
explored whether those blastocysts producing a large number of TE cells can “donate” 8-20 cells 
to a sibling blastocyst with poor TE health in the form of a cellular graft. This graft would aid the 
latter sibling blastocyst in continued development, increasing its potential for success and 
likelihood of selection for cryopreservation to use with future uterine transfers, eventually in 
human IVF. The purpose of this study, then is to introduce a laboratory technique using blastocysts 
of the mouse, Mus musculus, which takes advantage of the adhesion properties of cells, specifically 
E-cadherin proteins during micromanipulation. I aimed to validate a technique, which may 
eventually enable rescuing of poorly growing human blastocysts (from a fate of discard) without 
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disruption of ICM cells. Specifically, I hypothesized that chromosomally different transplanted 
trophoblast cells from sibling blastocysts are able to rescue a poor quality sibling blastocyst’s 
development.  
 
3.2 Materials and Methods 
 Source of and Description of Embryos 
Mouse embryos were purchased from EmbryoTech Laboratories (Haverhill, MA) in 
cryopreserved straws of 10 or 20 2-cell stage embryos per straw. A total of two batches were used 
during the study (B2-2016416 and B2-10915). Institutional animal care and use committee 
(IACUC) approval was obtained for this study, 15019, from the University of North Texas on 
September 02, 2015 (Appendix D). 
 
 Thaw and Culture 
All cultures were performed in incubators (Sanyo MCO-5M) programmed for 6.2% CO2 
and 5.0% O2 .Gas values were verified daily by a G100 handheld analyzer (ViaSensor). An example 
of a calibration curve for this device is presented in figure 3.1. The day prior to embryo thawing, 
one 35mm Petri dish (Thermo Scientific™ 153066) was prepared with seven-40μl drops of culture 
medium, G1TM Plus (VitroLife, 10128) for equilibration, in which the embryos will grow for the 
first 3 days then G2 TM Plus for days 3-6 (VitroLife, 10132). Each dish was overlaid with 4ml of 
culture oil (VitroLife, 10029). On the day of thaw, one straw containing either 10 or 20 2-cell 
mouse embryos was removed from the cryotank and held at room temperature for 2-3 minutes. 
The straw was then placed in a 37˚C water-bath for one minute to complete thawing. The lower 
end of the straw was cut to expel cryo-media containing the embryos and upper end was cut 
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between the plug (appendix A). A rod was used to depress the plug and expel the embryos onto a 
dish. The embryos were found and rinsed in a 100μl drop of modified human tubal fluid (mHTF) 
(Sage, ART-1023) supplemented with 10% protein (Irvine, 99193) using an Eppendorf 
micropipettor. The embryos were rinsed in a second 100μl drop of mHTF then moved to the third 
100μl drop of mHTF and allowed to equilibrate for 10 minutes at room temperature. At the end of 
the thawing period, the embryos were placed in a pre-equilibrated G1 Plus dish of culture medium 
and left in the incubator overnight.  The day of the thaw was day 1 of embryonic development. 
Embryos were moved to G2 Plus medium on day 2 of culture thru day 6. 
 
Figure 3.1. Calibration curve. G100 handheld analyzer was verified for accuracy and used to 
collect all of the daily incubator chamber gas measurements. The line of identity (Blue) is plotted 
as well as the analyzer measured values against the actual values. 
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 Definition of Outcome and Terminology 
Recipient blastocysts are sibling blastocysts that received a graft. Donor blastocysts are 
blastocysts, which donated either ICM or TE cells to the recipient blastocyst(s) (Note: Recipient 
and Donor terms are used differently in this chapter as opposed to subsequent chapters, in which 
donor refers to individual human patients that donated gametes and recipients refers to individual 
human patients who accepted gametes from donors). Grafts are defined as either 8-20 TE or ICM 
cells that were removed from sibling donor blastocysts and transplanted to the sibling recipient TE 
cells. Success is defined as positively integrated graft cells with the recipient’s sibling TE.  
 
 Technique Overview 
An overview of this technique is presented in figure 3.2, in which the top of the figure 
demonstrates a high quality blastocyst that has a proper inner cell mass (ICM) and trophectoderm 
(TE) cells. The next two blastocysts have either the ICM or TE cells developed poorly, resulting 
in blastocyst discard. The proposed technique of micromanipulation of the blastocysts, in which 
either ICM or TE develops poorly is demonstrated in the lower half of the figure. The first scenario 
(A) depicts how a good piece of one blastocyst (ICM) could be transplanted into the good piece of 
a sibling blastocyst (TE). Once performed, it would result in one high quality blastocyst by 
combining the strong cell types from two poor quality blastocysts. Alternatively, as shown in 
scenario B, a blastocyst with well developed ICM and TE cells could donate 8-20 TE cells to a 
sibling blastocyst, which has developed a high quality ICM but a poor quality TE, creating a fair 
quality blastocyst. Ultimately the number of high quality blastocysts per IVF treatment would be 
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Figure 3.2. Technique overview. The large solid lined circle represents a good quality 
trophectoderm (TE) in blastocyst and the hashed circle represents a poor quality TE. The smaller 
oval circles shaded solid gray are representative of good quality inner cell mass (ICM) where as 
the hashed smaller oval circles are poor quality ICM. A good quality ICM can be grafted from one 
blastocyst containing a poor quality TE into a sibling blastocyst that has a good quality TE but a 
poor quality ICM. This allows for the creation of one high quality blastocysts from two poor 
quality initial sibling blastocysts. Alternatively, one high quality sibling blastocysts can donate 8-
20 good quality TE cells to sibling blastocysts, which have a high quality ICM but a poor quality 
TE creating a fair quality blastocyst. Courtesy: W.W. Burggren, UNT. 
 
 Study Organization and Grouping of Blastocysts 
Modified human tubal fluid (mHTF) medium, a synthetic solution composed of HEPES 
buffering system with protein supplement, was used to determine if the adhesion success of grafts 
is higher without disruption of E-Cadherin bonds in blastocysts. Additionally, calcium/magnesium 
free medium was used during cell grafting procedures to determine if the interim dissociation of 
E-Cadherin-catenin bonds in the recipient blastocyst, temporarily exposing recipient cells proteins 
to donor graft cell’s proteins, will improve graft adhesion after transplantation and restoration of 
calcium in the medium. The study included 155 thawed 2-cell mouse embryos. Due to their early 
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embryonic developmental arrest prior to treatment, 16 embryos were excluded from the study. The 
remaining 139 embryos at the blastocyst stage were divided in two groups: Group A (n=97) with 
modified human tubal fluid (mHTF) medium, (Irvine Scientific, 90126) used at treatment; Group 
B (n=42) with GPGD (VitroLife, 10074) medium used at treatment.  
Figure 3.3. Study organization. Control blastocysts were exposed to treatment medium; however 
they were not exposed to cell ablation via Saturn laser pulses. Mouse blastocysts were organized 
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The study organization is depicted in figure 3.3. In Group A, 42 total blastocysts were 
divided into three subgroups: control (n=16), donor (n=31) and recipient (n=50). Blastocysts in 
group B were similarly divided in three subgroups: control (n=10), donor (n=16) and recipient 
(n=16). Recipient blastocysts in groups A and B each either received inner cell mass (ICM) grafts 
(Group A, n=26 and Group B, n=8) or trophectoderm (TE) grafts (Group A, n=24 and Group B, 
n=8). 
 
 Blastocyst Cell Grafting 
For each round of embryo thaw, the graft transplant was scheduled on day 4 in one half of 
the treatments and day 5 on the other half to determine if success was stage-dependent. On the 
scheduled graft transplant day, selected blastocysts based upon grouping were placed in a dish 
(Falcon, 353655) pre-warmed to 37˚C. The dish consisted of 10 - 10μl drops of either mHTF or 
GPGD and overlaid with 4ml of culture oil. Cells isolation of grafts, previously described, was 
performed using the Saturn laser, which consists of 1480nm / 400mW solid state diode laser with 
a pulse length range 0.005-2.0ms / 5-2000µs and is embedded in a 40X objective. For the 
procedure, control, donor and recipient blastocysts were all placed in the treatment dish in 
individual microdrops for isolation, number assignment and tracking. The dish was placed on the 
inverted microscope (Olympus IX70) for the entire duration of treatment (30-40 minutes), in which 
all blastocysts were exposed to the treatment solution for the same duration.  
 
3.2.6.1 Control Blastocysts  
Control blastocysts neither received nor donated cells to any other blastocyst nor were 
exposed to the Saturn laser. The viability, blastocoel expansion cell symmetry and granularity of 
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the control group for both group A and B was assessed one day post procedure. This group was 
used as a reference for quality comparison of embryos in treatment groups to determine if a decline 
in blastocysts quality emerged and if so, was the contributing factor the treatment solution or laser 
exposure.  
 
3.2.6.2 Donor Blastocysts 
Blastocysts in the donor group donated 8-20 TE or ICM cells, referred to as grafts, to the 
recipient sibling blastocysts. To isolate a graft from the donor, each blastocyst was positioned 
between a holding pipette (VitroLife, 14393) and biopsy pipette (VitroLife, 15123) under the 
microscope. The pulses from the laser were emitted at 3.67ms (3.9μm pulse width/hole size). The 
graft was removed from the donor and held inside the glass biopsy pipette.  
 
3.2.6.3 Recipient Blastocysts 
Immediately after the graft had been isolated from the donor, the dish was repositioned and 
the pipettes were introduced to the microdrop containing a recipient blastocyst, which were 
recipients of the graft cells. To accomplish this, the recipient blastocyst was held against the 
holding pipette and the zona pellucida was ablated to create an opening of approximately 15μm 
(figure 3.4A). The biopsy pipette containing the graft was advanced towards the zonal opening 
and the graft was carefully inserted through the recipient’s zona pellucida taking proper 
precautions that the side of the graft with ablated cells was in contact with the recipient’s 
trophectoderm (figure 3.4B, C). Once the graft was placed in the recipient’s zonal region, the 
pipette was advanced into the blastocyst to promote collapse of the recipient’s blastocoel. As the 
blastocoel collapsed, it created room for the graft to properly position inside its zona pellucida 
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(figure 3.4D, E). Finally, the biopsy pipette was pressed against the recipient’s zona pellucida to 
promote contact of graft at the site of ablation with the recipient TE. Once the recipient blastocyst 
began to re-expand its blastocoel and exert pressure on the graft (held in position by the zona), 
cells were in the optimal position for successful annealation with sibling TE (figure 3.4F). At the 
end of the procedure, all blastocysts were returned to the G2 Plus culture dish and placed 
individually in 40μl drops for overnight culture. 
 
Figure 3.4. Cell grafting procedure. Cell grafts were performed on Olympus IX70, inverted 
compound microscope using a 40X Saturn laser objective. Grafts were ablated using the Saturn 
laser embedded in a 40X objective, removed from donor blastocysts and transplanted using a 
micromanipulation pipette into the zona pellucida of a sibling recipient blastocyst.  
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 Assessment of Graft Transplantation Success 
One day post treatment, all blastocysts were microscopically assessed, using an Olympus 
IX70. Measured parameters included viability, blastocoel expansion, distinct inner cell mass 
compaction, trophectoderm cell symmetry and granularity. Recipient blastocysts were additionally 
assessed at the graft site to determine if the graft successfully annealed. Next the blastocysts were 
fluorescently stained for further confirmation of success, which is now discussed.  
 
 Fixation and Microscopy 
Blastocysts were placed in a 20 µl drop of fixative prepared by adding 100 µl of 3.7% 
formaldehyde (Millipore Sigma, b1040022500) in PBS (phosphate buffered saline) (Fisher 
Scientific, BP24384) and incubated for 5 minutes at room temperature. Following fixation, the 
blastocysts were permeablilized using Triton™ X-100 for 5 minutes. This solution was prepared 
by adding 50µL of Triton X-100 (Sigma-Aldrich, X100-5ml) to 49.95 ml PBS. Blastocysts were 
then washed twice with block solution formulated with 3% Bovine Serum Albumin (BSA), 40 ml 
of PBS and 50 μl of Tween 20 (Sigma-Aldrich, P19379) with 2 minutes between washes.  
Next, DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) (Sigma-Aldrich, D9542-
1MG, excitation spectrum 358/461nm) solution was prepared by diluting 1 μl of 0.5 mg/ml DAPI 
in 100 μl of block solution. The nuclei/DNA were stained by incubating the blastocysts in DAPI 
solution for 5 minutes. The blastocysts were then rinsed twice in block solution of 100 μl drops 
with two minutes in between each rinse. For examination, blastocysts were placed in 2 μl drops of 
stock solution on a glass slide. After 5 seconds, a drop of Prolong-Gold anti-fade mountant (Fisher 
Scientific, P36934) was expelled on the blastocysts and covered with a glass cover slip. Slides 
were held at 4˚C for a maximum of 2 days until examination. Laser scanning confocal microscopy 
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was carried out with Zeiss LSM710, laser scanning confocal microscope (Carl Zeiss, Inc, 
Thornwood, NY, USA), equipped with a 25 mW 405 nm diode laser, a 25 mW multi-line Argon 
laser (458, 488, and 514 nm), a 20 mW 561 nm DPSS laser, and a 5mW 633 nm HeNe laser. The 
images are presented as single 4μm thick optical sections. 
 
 Data Analyses 
Morphologic assessment was performed of all blastocysts using the SART grading system 
(Heitmann et al. 2013). All blastocysts were assessed for expansion of the blastocoel, 
trophectoderm cell symmetry and granularity. Additionally, recipient blastocysts were assessed 
for graft integration and adhesion. A decision tree construction was performed with the 
evolutionary tree algorithm (Evtree) using R software (Grubinger et al. 2014; Fan and Gray 2005) 
(see Chapter 2). The receiver operating characteristic (ROC) curve analysis, which illustrates the 
Evtree’s diagnostic ability as the discrimination threshold is varied for the statistical computation  
(Robin et al. 2011) was performed (see Chapter 2). This curve calculates the rate of sensitivity 
given the optimal specificity. With both specificity and sensitivity computed, an overall accuracy 
of the model was calculated. 
 
3.3 Results 
 Microscopic Assessment One Day Post Graft Transfer 
Upon examination, most recipient blastocysts demonstrated one of two conditions: either 
strong annealation of TE cells to sibling grafts or failure to anneal with the graft where the graft 
either moved away from the recipient or was attretic (figure 3.5A-C). In figure 3.5A, graft cells 
were grouped together and initiated a blastocoelic cavity formation separate from the recipient. 
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Additionally, there were blastocysts that successfully merged with the grafted cells and continued 
development (figure 3.5D-F). In these images, the black arrows show the location of annealation 
between the recipient TE and sibling graft. Figure 3.5D demonstrates two hatching points in the 
recipient zona pellucida. The TE cells hatching from the bottom left belong to the recipient whereas 
the cells herniating from the top left are the grafted cells identified by the black arrow (successful 
cell annealation). 
 
Figure 3.5. Graft success evaluations. Representative blastocysts of successful versus unsuccessful 
graft adhesion Recipient blastocysts were assessed one day post graft procedure for evaluation of 
successful graft integration in sibling TE cells. Images are labeled to indicate which solution was 
utilized during procedure. Successful proper attachments (A-C) are identified with black arrows. 
Improper attachments of the grafts (D-F) were identified as isolated group of cells from the 
developing recipient blastocyst and are labeled with white arrows.  
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3.3.1.1 Treatment of Graft Transfer on Day 4 
1) mHTF Solution (group A): Representative day 5 blastocysts are shown in figure 3.6A-
B. Control blastocysts exhibited full expansion of blastocoel, symmetry of TE and distinct 
compaction of ICM. Recipient blastocysts (figure 3.6B) also showed full expansion of blastocoel 
on day 5 of development, symmetrical cell pattern present throughout the TE and distinct 
compacted ICM. Additionally, the graft cells were apparent and site of annealation was clearly 
observed with a majority of cells at the ablation site in contact and integrated with the recipient 
TE. No granularity of TE was observed.  
 
Figure 3.6. Blastocyst qualities by treatment.  Blastocysts evaluations were performed one day 
post graft transplant and exposure to treatment solution. Representative images of blastocyst 
qualities observed on day 5 of development post treatment on day 4(A-D). mHTF treatment group 
on day 4 were overall the highest quality on day 5 (A, B). Blastocysts showed overall the lowest 
morphology with exposure to GPGD on day 4 (C, D). Blastocysts on day 6 exposed to mHTF (E) 
demonstrated expansion of the blastocoel, symmetry throughout the TE and defined cell borders 
(F, H). However, full expansion was not observed in this group (G-H).  
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2) GPGD Solution (group B): Control blastocysts on this day showed increase in cell 
granularity, blastocoelic cavity collapse and a highly inconsistent and asymmetrical pattern of 
trophectoderm cells. (figure 3.6C). Recipient blastocysts on day 5 similarly showed profuse 
collapse of the blastocoel within and outside of the zona pellucida accompanied by increased 
granularity in cell morphology (figure 3.6D). TE cells were largely asymmetrical on the recipient 
blastocyst. Graft cells, although identifiable, did not demonstrate strong integration with recipient 
TE cells. Due to blastocoelic collapse, cell borders were difficult to distinguish for evaluation of 
cell viability.  
 
3.3.1.2 Treatment of Graft Transfer on Day 5 
1) mHTF Solution (group A): Control blastocysts were fully to partially expanded, 
displayed symmetrical TE cells, ICM was compact and identifiable and cell granularity was absent 
(figure 3.6E). The overall expansion patterns of the recipient blastocysts, likewise, ranged from 
fully expanded to partially expanded blastocoelic cavities (figure 3.6F). TE cells were symmetrical 
and ICMs were compacted and distinct. Clear and concise cell borders were observed throughout 
the blastocysts and no cell granularity was observed. Grafts were identifiable and demonstrated 
annealation, when successful, of all cells at the ablation site in contact and integrated with the 
recipient’s TE. Little to no degeneration of cells on grafts at the ablation site was noted.  
2) GPGD Solution (group B): Control blastocysts exhibited partial expansion of the 
blastocoel. Figure 3.6G shows four control blastocysts, of which three are partially expanded and 
one shows complete collapse of the blastocoelic cavity representative of morphology for this 
group. Symmetry of the TE is moderate in blastocysts with at least partial blastocoelic expansion. 
For recipient blastocysts, the morphology on day 5 similarly varied slightly ranging from partial 
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expansion of the blastocoel to complete collapse (Figure 3.6H). Full expansion of the blastocoel 
was absent in all of the recipient blastocysts. Although present, granularity was slightly less 
evident in the recipient TE cells compared to graft transfer one day earlier in this solution. Due to 
the partial to full collapse of the blastocoel, the cell borders were less prominent. Grafts were 
apparent, but the overall annealation resulted in 4-6 cells integrated in the recipient’s TE with the 
remaining cells at the ablation site degenerating and failing to anneal.  
 
 Nuclear Staining Assessment 
Single optical sections of recipient blastocysts were analyzed for the interaction between 
the nuclear pattern of the graft cells and the recipient trophectoderm cells. Nuclei stacked linearly 
against the recipient TE indicated failed integration of grafted cells. A netted pattern of graft cell 
nuclei with continuous extension in recipient TE would, however, indicate a positive annealation 
and integration with the recipient sibling blastocyst. Figure 3.7A is representative of a recipient 
hatching blastocyst that was successful in incorporating the sibling graft with its TE. The white 
arrow on the left of the image points to a linear nuclear pattern of the graft that is folded along one 
side of the sibling TE (no integration on this part of the graft) and the gray arrow on the right of 
the image shows the area of the graft that has successfully integrated with the recipient blastocyst 
trophectoderm, displaying a netted pattern of nuclei extending from the graft cells and continuous 
throughout the recipient cells. Figure 3.7B shows a blastocyst expanded within its zona pellucida 
with failed attachment of the graft. The arrow is pointing to the graft which has failed to integrate, 
demonstrated by the stacked linear nuclear pattern along the side of recipient TE cells. The netted 




Figure 3.7. Fluorescent nucleic acid staining. Blastocysts that successfully accepted the sibling 
graft demonstrated a netted integration of cell nuclei that was continuous from the graft throughout 
the recipient TE (A) depicted by the gray arrow. When the graft was unsuccessful or the portion 
of the graft cells not directly integrated with the sibling TE appeared as a stack linear organization 
of cell nuclei (B) depicted by the white arrow.  
 
 Evtree Analysis for Graft Cell Adhesion 
The success for each recipient blastocyst was measured by a confirmed attachment of the 
graft, whereas all other outcomes were labeled as no attachment (including attretic grafts or attretic 
blastocysts). Using this measure as the final outcome a decision tree analysis was performed in R 
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software using Evtree (see Chapter 2) (Grubinger, Thomas,  Achim, and Pfeifer, Karl-Peter 2014). 
According to the prediction model (figure 3.8), the type of cells in the cell graft (TE or ICM) was 
not a factor that impacts outcome and so was not displayed on the final tree. The medium, in which 
the blastocysts were placed during the graft procedure had the greatest impact on outcome (figure 
3.8, node 1). Day of the graft transplant was the second factor which determined outcome success 
(node 2).  
 
Figure 3.8. Evtree for graft cell adhesion.  This prediction model was determined by Evtree in R 
software. Final graphed nodes depict highest predictive success of graft adhesion when 
transplantation is performed on day 4 using mHTF as procedural medium (Node 3) with 
approximately 70% success. 
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Graft procedures using mHTF had the highest success (70%) in graft integration with the 
recipient sibling trophectoderm when grafts are transplanted on day 4 of development (node 3, 
n=28).When graft transplants were performed on day 5, success decreased to ~25% (node 4, n=22). 
Transplants performed in GPGD had 30% success in graft attachment to the recipient’s 
trophectoderm (node 5, n=16). 
 
 Accuracy Determination of Evtree Analysis 
Evtree analysis yielded an accuracy of 71% with an error rate of 29% (figure 3.9). The 
ROC curve had an area under the curve (AUC) of 0.71 with 95% confidence interval (CI) of 0.6-
0.8, indicating that any final node of the decision tree results in 10% greater success than chance 
alone as the lowest measure and up to 30% greater success than chance alone at its highest success. 
 
Figure 3.9. Receiver operator characteristic curve: cell adhesion. The receiver operator curve for 
Evtree analysis of graft cell adhesion. True positive rate (sensitivity) is plotted against the false 
positive rate (1-specificity). The vertical lines represent 95% confidence intervals.  
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3.4 Discussion 
Numerous techniques offer exclusion criteria to aid in the selection of one superior 
blastocyst from a group of sibling blastocysts for uterine transfer to optimize pregnancy outcome. 
These techniques include morphology assessment, preimplantation genetic screening and 
morphokinetic assessments with tools such as time-lapse microscopy (Fragouli and Wells 2012; 
Capalbo et al. 2014; Mumusoglu et al. 2017). There are limited inclusion methodologies for 
individuals at risk of poor outcome, such as no high quality blastocysts produced per treatment, 
which may incorporate poor quality embryos. The technique of the present study provides an 
inclusion method for IVF, increasing the number of high quality blastocysts created per treatment 
from graft donation of sibling blastocysts.  
 
 Stage-Dependent Graft Success 
In the present study, on days 5 and 6 of development, the blastocysts were expected to 
demonstrate full blastocoelic cavity expansion, concise visible cell boarders, compacted and 
distinct inner cell mass cells, symmetry in trophectoderm cells and no granularity in cell 
morphology. The grafts were expected to show the above mentioned morphology as well as clear 
distinct incorporation of annealed cells into the recipient blastocysts’ TE for treatment groups. The 
adhesion of the trophectoderm cells in blastocysts was assessed for successful integration of donor 
cell grafts from sibling blastocysts by microscopy and fluorescent nucleic acid staining. The 
resulting images suggest that successful graft integration is stage-dependent. Grafts transplanted 
on day 4 of development (day after morula stage) had the combination of highest rate of successful 
graft adhesion and stage appropriate growth of full blastocoel expansion with symmetrical, 
agranulated cell morphology in the mHTF medium. Trophectoderm cell junctions in the 
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blastocysts, when not disturbed during development (removing calcium from the medium) 
provides optimum conditions for annealation and incorporation of sibling graft.  
Both mHTF and GPGD media treated control blastocysts on day 4, displayed the same 
pattern of morphology on day 5 as the treatment group of recipient blastocysts, which also 
displayed incorporation of grafts. However, blastocysts treated with GPGD failed to re-expand 
their blastocoel indicating a loss of functionality essential for continued development. Exposure to 
GPGD at this stage has contributed to this difference in morphology and growth potential, 
confirming GPGD’s contribution to the blastocysts’ inability to completely re-expand post-
treatment. Most conspicuous is the presence of severely granulated cell morphology observed in 
blastocysts treated with GPGD on day 4. This morphology was absent in blastocysts treated with 
mHTF at the same stage indicating the removal of calcium in the blastocyst’s environment caused 
a negative effect. This is contrary to the expected temporary disruption by GPGD of E-Cadherin 
to catenin bonds. In human blastocysts, Alikani (Alikani 2005) showed that poorly developed TE 
cells demonstrate a perturbed distribution of E-Cadherin, which became more erratic or absent as 
the blastocyst continued growth. This inability of the poor quality TE to properly redistribute E-
Cadherin may plausibly explain their inability to recover post exposure to GPGD in the current 
study.  
 
 Role of Trophectoderm Junctional Proteins 
The trophectoderm and inner cell mass communicate through gap and tight junctions as 
well as other structures (Fleming et al. 2000; Ren et al. 2016; Watson and Barcroft 2001). 
However, blastocysts with abnormal morphology have both altered expression and function of 
these junctional proteins (Hardy et al. 1996). Images obtained in the current study indicate that 
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obstruction of these junctions, particularly in blastocysts with fewer TE cells result in lowered 
ability of the blastocyst to properly redistribute and continue expression of these essential proteins. 
Earlier stage blastocysts on day 4 are able to recover in the form of partial blastocoelic expansion 
whereas later stage blastocysts demonstrated loss of this ability. When grafts were transferred on 
day 5, exposure to GPGD was delayed by one day and partial expansion of the blastocoel was 
observed on day 6. The cell adhesion provided by E-Cadherin, expected to increase in number of 
bonds with continued cell divisions, establishes the tight junctional seal and maintains the 
polarized Na/K-ATPase distribution essential to blastocoelic expansion (Watson 1992; Harris and 
Tepass 2010). Therefore, delaying the graft procedure and exposure of blastocysts to GPGD to 
day 5 provided time for further development and maturation of trophectoderm cells in the 
blastocyst, conceivably explaining the partial recovery of the blastocoel.   
A major reason blastocysts fail to implant is the improper formation of trophectoderm cells, 
evident from low cell numbers and cell asymmetry as examined prior to uterine embryo transfer 
in human IVF (Alfarawati et al. 2011; Capalbo et al. 2014). Blastocysts of this low quality are, 
therefore, not suitable for cryopreservation due to lower implantation rate and survivability from 
the cryopreservation procedure (Capalbo et al. 2014). Currently these blastocysts are discarded in 
IVF treatments. The trophectoderm cells support the developing fetus during pregnancy and have 
differentiated from the fetal cells or the ICM, an irreversible action (see Chapter 1).  
 
 Implications for Human IVF 
In light of our findings I suggest that sibling trophectoderm grafts, chromosomally different 
from the recipient trophectoderm, can improve development of poor quality blastocysts and 
possibly support pregnancy by contributing to extra-embryonic structures, previously described 
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(see Chapter 1). Donation of 8-12 TE cells to a sibling blastocysts will not violate any genetic 
integrity of the developing fetus, therefore providing aid in implantation and placental support of 
its sibling only. This is may be compared to a blood transfusion where the donation of blood cells 
of one genetic person can aid in sustaining life of a genetically different person, however, not 
altering the blood recipient’s ability to express their own genome. 
Eventual use of graft transfer embryonic stem cells (GT-ESC) in human IVF is expected 
to demonstrate a 10-15% increase in high quality blastocyst production per treatment in poor 
prognosis patients. This inclusive technique will decrease excessive administration of ovarian 
stimulation medication used to produce a large number of mature oocytes during IVF treatments 
to increase odds of pregnancy outcome. Lower gonadotropin use will decrease treatment costs per 
patient and lower incidences of ovarian hyperstimulation syndrome, supporting advancement of 
the field of reproductive medicine. This is especially important for patients who are diagnosed 
with diminished ovarian reserve (DOR) or preliminary ovarian failure (POF) whose treatment 
often does not produce a high number of ovarian follicles and subsequently, lower numbers of 
high quality blastocysts per round of IVF. Although a pregnancy can be achieved with just one 
blastocyst, failure to produce additional blastocysts available for cryopreservation for future use, 
leads to suboptimal use of patient financial resources as well as increased emotional stress.  
 
3.5 Conclusion 
Analysis of the images in this study support the explanation that failure of proper blastocoel 
formation is highly associated with the Na/K-ATPase activity or lack thereof (Câmara et al. 2016; 
Lafond et al. 1991). The implications of temporary disruption of junctions as well as role of Na/K-
ATPase in the incorporation of high quality TE cells from sibling blastocysts are therefore well 
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worth investigating. This is especially important to the application of our technique to human IVF, 
particularly individuals with poor prognosis such as patients diagnosed with DOR or POF who 
would most benefit from this method. Especially for this group of patient’s the availability of graft 
transplants to sibling blastocyst may be the most successful option for a live birth. The eventual 
clinical application will require evaluation of the recipient blastocyst’s integrity prior to 
consideration for uterine transfer, i.e., preimplantation genetic screening. The potential pairing of 




EFFECTIVENESS OF PRE-IMPLANTATION GENETIC SCREENING USING NGS, aCGH 
AND SNP MIRCROARRAY FOR IN-VITRO FERTILIZATION TREATMENTS 
4.1 Introduction 
Aneuploidy, the presence of unbalanced or abnormal number of chromosomes in cells, is 
more prevalent in individuals with recurrent pregnancy loss (Atasever et al. 2016; Hatirnaz et al. 
2017; Hodes-Wertz et al. 2012) and unexplained implantation failure (Hatirnaz et al. 2017). 
Aneuploidy is one of the most common form of genetic error found in zygotes and early embryos 
(Handyside et al. 2012; Gleicher et al. 2014; Dahdouh et al. 2015). To screen possible defects, pre-
implantation genetic screening (PGS) of embryonic cells prior to uterine transfer is recommended 
in IVF treatments to reduce failed attempts at embryo implantation and pregnancy losses. Since 
the early 1990’s chromosomal screening methods have been available to IVF laboratories to detect 
genomic anomalies in developing embryos (Gleicher and Orvieto 2017; Speleman et al. 1992). 
Since the development of PGS, the primary focus of IVF has been to maximize pregnancy outcome 
via screening and prevention of aneuploid embryos transferred (Delhanty et al. 1993; Munné et al. 
1993; Handyside 2013). Despite this relatively long history of genetic screening, there remains a 
lack of consensus on the most effective method of screening embryos for IVF treatments. 
Approximately 5% variability exists in efficiency of array comparative genomic hybridization and 
next generation sequencing techniques (Aleksandrova et al. 2016). aCGH was advocated as the 
method of choice for screening of embryos, specifically for women of advanced maternal age 
(Handyside et al. 2012). 
Array comparative genomic hybridization (aCGH) has been successfully used in IVF 
worldwide as a means to screen all 23 pairs of chromosomes in developing embryos (Adler et al. 
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2014; Yang et al. 2013; Greco et al. 2014). While aCGH was proven successful and reliable, other 
techniques have been introduced to further improve pregnancy outcome post embryo biopsy. 
Single nucleotide polymorphism array (SNP array), which distinguishes between homogeneity and 
heterogeneity, is successfully used in IVF (Treff et al. 2010; Lathi et al. 2012). Changes in 
chromosome copy number and deletions or duplications of part or whole chromosomes can also 
be identified (Li et al. 2014). An added benefit to this technique compared to aCGH is that it can 
detect uniparental disomy, confirm parentage and detect some mosaic cell lines, embryos with 
more than one population of cells with different genotypes. 
The most current screening method, next generation sequencing (NGS), was introduced to 
IVF in 2007 (Goodwin et al. 2016; Yang et al. 2015; Wells et al. 2014). This technology is high 
throughput and can detect mosaic lines in samples, translocations and triploidy. Despite the 
availability of the improvement in read depth, there is no confirmation that NGS methodology 
improves implantation and pregnancy rates overall compared to aCGH or NGS. The description 
of each PGS technique, performed by reference laboratories, is discussed next. 
 
 PGS Methodologies  
aCGH: Whole genome amplification of cells was performed by Reprogenetics Laboratory 
(BlueGnome, Breaks House Mill Court, Great Shelford, Cambridge, CB22 5LD, UK) using 
24Sure. This array is based on bacterial artificial chromosomes (BACs) with greater than 5000 
DNA clones that are not documented to occur in disease regions, which covers 30% of the entire 
genome. Once the products are amplified, the test sample is hybridized with the control sample on 
the array. Both the control and test sample are differentially labeled with florescent probes and the 
ratios are interpreted. Results are reported as euploid, monosomy of certain chromosome(s), 
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trisomy of certain chromosome(s), or complex abnormal (multiple chromosome duplications or 
deletions). 
NGS-targeted amplification regions: Developed by the Johns Hopkins PGS team (Hallam 
et al. 2014), targeted next generation sequencing technique differs from whole genome 
amplification NGS in that “targeted” regions of the genome are amplified. Targeted NGS by 
EmbryVu (GoodStart genetics laboratory, Cambridge, MA) lowers the overall cost of the test by 
only amplifying regions to be read and tested. A single PCR primer amplifies the repetitive regions 
occurring on every chromosome. These regions have enough similarities for one primer to 
hybridize to all regions. However, these same regions have enough variance that they can be 
realigned back to their correct corresponding chromosome. The proportions of the repeats that 
align back to the chromosomes are used to then assess for aneuploidy. 
SNP array: Samples are processed using Illumina HumanCytoSNP-12 DNA BeadChips 
(Natera laboratory, San Carlos, CA) and results are interpreted using an informatics-based 
algorithm referred to as Parental Support (Johnson et al. 2010; Shi et al. 2013). The software 
references parental genotypes and distinguishes between balanced and unbalanced chromosome 
copy number, including uniparental disomy. The Parental Support algorithm statistically calculates 
the confidence scores to determine the accuracy of the genotype detected in the test sample. SNP 
array contains small fragments of the reference human genome, for which there are known multiple 
alleles (Adams et al. 2012; Schroeder et al. 2013). Each allele representation is present on the array 
and each position corresponds to a specific locus. The DNA from blastomeres is hybridized to the 
array, in which samples with allele A bind specifically to that allele on the array. 
Each PGS screening technique presents benefits over others and gives options to 
individuals that present with infertility (table 4.1).  
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Table 4.1. Comparison of preimplantation genetic screening techniques 
PGS 
Technique 
Description Cost Processing 
Time 






Test and reference 
DNA are labeled with 
different fluorescence 
probes and bind to 
complementary DNA 
on a slide. A 1:1 ratio 
results in a euploid 
interpretation. More of 
one fluorescence results 










translocations          
 • More expensive 





• Cannot detect 
Uniparental disomy or 
triploidy  
• No simultaneous 
PGD can be 
performed 
Balanced cost, time 
and 
comprehensiveness 





 Reference chip 
contains DNA SNPs 
(single nucleotide 
polymorphisms) which 
test sample binds to. A 






 7-14 days  •Can be done with 
parental support to 
compare allele 
patterns of parents 
to offspring, 
Uniparental 
disomy can be 
detected. 






 •Higher cost than 
aCGH 
• Requires WGA 
• Requires screening 
of parent DNA for 
parental support 












 Sample DNA is 
fragmented and tagged 
cDNA library is 
created. 
Complementary 
nucleotides are added 
and incorporated, in 
which a sequencer can 
detect a labeled 
fluorescence (Illumina 
HiSeq). Resulting 
sequences are aligned 
to reference genome 
and chromosome copy 
numbers are calculated. 
 $150
/read 











•Targeted NGS is 
possible, WGA 
not required 
 •WGA required for 
non-targeted NGS 
•Read depth can be 




significance labeled as 
aneuploid 










 None Embryos selected for 
transfer based on 
morphology 
n/a   n/a  •Fresh transfers 
are possible 
 •May need multiple 




miscarriages and risk 
of viable aneuploid 
gestation 
Lower financial 
burden on patients 
 
The current study evaluates the pregnancy and implantation rates of NGS screening 
compared to aCGH and SNP-microarray screening. The objective of this study is to determine 
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which of the three PGS techniques result in higher pregnancy and fetal viability rates. I hypothesize 
that SNP array technique, which offers a high sensitivity along with determination of parental 
origin, is superior to NGS or aCGH in achieving the highest success rates for IVF treatments with 
transfer of euploid embryos. There is limited information on the efficiency of NGS in a clinical 
setting for IVF patients, so this study also provides additional information on the acceptability of 
NGS for clinical use in IVF patients. 
 
4.2 Materials and Methods 
 Source of Embryos 
This study is a retrospective and prospective analysis of treatments of human patients 
performed at a single clinic, Dallas IVF, referred to as “the Center5.” The observational data 
includes all frozen embryo transfer (FET) treatments from a two year period (January 1, 2015 to 
December 31, 2016) that fit specific inclusion criteria (discussed below). The data for treatments 
included in this study were retrieved using an electronic database management system, in which 
the data were de-identified to remain in compliance with Health Information Portability and 
Accountability Act (HIPAA).  
 
 Standard Patient and Embryo Treatment 
For all screening groups, individuals underwent controlled ovarian stimulation using 
gonadotropins followed by transvaginal oocyte retrieval. Individual dosing and all medical 
procedures related to the in vitro fertilization IVF treatment were performed by licensed and board 
                                                 
5 Dallas IVF is a registered member of the American Society of Reproductive Medicine and a Society of Assisted 
Reproductive Technology. The facility is accredited by College of American Pathology (CAP), Clinical Laboratory 
Improvement Amendments (CLIA) and is registered with the Food and Drug Administration (FDA). 
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certified physicians. I performed all in vitro fertilization procedures with assistance from members 
of the Center’s embryology team to include: oocyte collection and trimming, culture maintenance, 
insemination of oocytes, daily embryo checks, trophectoderm biopsy, blastocyst vitrification, 
blastocyst warming and assistance in uterine blastocyst transfer. Oocytes were inseminated using 
partner’s sperm. All embryos were cultured for a period of 5-6 days, at which they were 
cryopreserved. All uterine embryo transfers were from warmed blastocysts.  
 
 Groups by Screening Method 
A total of 402 FET treatments were included in the study. Treatments were segregated into 
4 groups in accordance to the PGS technique used (Figure 4.1). Group A included 223 treatments, 
in which 305 of the total embryos transferred lacked the embryo biopsy procedure, but nonetheless 
underwent cryopreservation in the fresh IVF treatment followed by warming and transfer in the 
IVF treatment referenced. This group was used as a reference to evaluate the outcomes of the 
groups with pre-implantation genetic screening methods. The ploidy status of embryos in group A 
was unknown at embryo transfer for implantation. In groups B, C and D embryo biopsies were 
performed 5-6 days post oocyte fertilization during the initial in vitro fertilization treatments and 
the embryos were subsequently cryopreserved and biopsies were screened by a third party 
laboratory. Group B included 56 FET treatments consisting of 71 euploid embryos screened using 
aCGH analysis (Reprogenetics laboratories, LA). Group C included 50 FET treatments consisting 
of 63 euploid screened using NGS analysis (EmbryVu, MA). Group D included 73 FET treatments 





Figure 4.1. Grouping by screening method. Schematic for Frozen Embryo Transfer (FET) 
treatments included in each of the four groups. 
 
4.2.3.1 Inclusion Criteria 
Criteria for including embryos in this study are as follows: 
• Observations for individuals in a non-repeated case study only, in which individuals 
who attempted their first uterine embryo transfer in a frozen embryo transfer (FET). 
• All FETs, in which no trophectoderm biopsy was performed on the embryo during a 
fresh IVF treatment, where the embryo was cryopreserved at the blastocyst stage, were 
included in the reference group.  
• All embryos that underwent trophectoderm biopsy procedures were included in groups 
B, C and D depending on the PGS technique used.  
4.2.3.2 Exclusion Criteria 
Criteria for excluding embryos from this study are as follows: 
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• Individuals who used donated gametes (oocytes or sperm cells).  
• Individuals that did not have any embryos to cryopreserve or received at least one 
embryo transferred in the uterus during the fresh IVF treatment. 
• Secondary FET treatments following a failed primary FET treatment.  
• Embryos that were originally cryopreserved in fresh treatments and were warmed, 
biopsied and re-vitrified with the intension of re-warming only euploid embryo(s) for 
transfer in a subsequent FET. 
• Adopted embryos that would represent the primary FET for a recipient 
• Embryos that were not cryopreserved by the Center. 
• Individuals who utilized more than one technique in an IVF treatment. 
 
 Embryo Culture and Trophectoderm Biopsy 
Embryos were cultured in sequential media (VitroLife, G Series) for a period of 6 days in 
incubators set at 6.2% CO2 and 5% O2 (Sanyo MCO-5M). Upon evaluation of morphokinetic 
parameters of blastocyst development, the embryos were selected for trophectoderm biopsy. Each 
embryo was placed in a culture dish (Falcon 353655) with 5 μl drops of modified human tubal 
fluid (mHTF) (Irvine Scientific, SWM 9983-100) overlaid with 4 ml of culture oil (VitroLife, 
10029). The embryos were placed individually in drops and the dish was placed on a heated stage 
(TokaiHit, heated plate) with temperature maintained at 37˚C. Biopsies were performed on an 
inverted microscope system (Olympus IX70) by ablation of trophectoderm cells using a Saturn 
Laser 40X objective. The Saturn Laser Lens consists of 1480 nm / 400 mW solid state diode laser 
with a pulse length range 0.005-2.0 ms / 5-2000 µs.  A total of 4-6 cells were removed from the 
embryo and the cells were washed through 4, 20μl drops of wash buffer provided by each of the 
genetic testing centers. Each biopsy was loaded into a DNA tube labeled with the embryo number. 
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The tubes were held at -30˚C for a minimum of 2 h and then packaged and shipped with dry ice 
overnight to the reference genetic laboratory.  
Amplification and interpretation of DNA from trophectoderm cells biopsied by the Center 
was performed by a reference laboratory. One of three techniques for the screening of biopsied 
cells to establish ploidy was utilized by the Center.  Upon recipient of PGS results from the 
reference laboratory, warming of euploid single or double embryo transfer procedure was planned.  
 
 Blastocyst Vitrification 
Immediately following the trophectoderm biopsy, blastocysts were individually vitrified 
(VitroLife, 10119). Each blastocyst was placed in Vitri 1 solution of the vitrification kit for 5 min 
for equilibration. The blastocyst was then placed in Vitri 2 solution of the kit for 2 min to initiate 
the cryoprotectants exchange. Finally, the blastocyst was placed in Vitri 3 solution for 45 sec to 
complete the vitrification process, in which the cells are dehydrated and the water volume within 
the cells is displaced by the cryoprotectants in the vitrification medium. This latter solution is 
viscous, which when frozen, results in extreme hardening to achieve a glass like state (Lowe et al. 
2015). Each blastocyst was loaded onto the Rapid-I (VitroLife, 14406) device and stored in liquid 
nitrogen until scheduled warming. 
 
 Selection of Blastocysts for Transfer 
Embryo selection for the reference group was made solely based on morphokinetic 
parameters. For the groups with PGS screening (B, C and D) selection was performed using a two 
tier method: euploid status followed by morphokinetics. In the screening groups, the highest 
morphologically graded one to two embryos were selected for warming on the morning of the 
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procedure from the embryos that were reported euploid through pre-implantation genetic screening 
(PGS). Embryos were graded using the Society of American Reproductive Technology (SART) 
guidelines (Racowsky et al. 2010).   
 
 Blastocyst Warming and Uterine Transfer 
Blastocysts were warmed using the Rapid Warm (VitroLife, 10120) kit, consisting of 
proprietary solutions. The Rapid I straw was removed from liquid nitrogen and submerged in 
Solution 1 of the Rapid Warm kit for 2 min. The embryo was then moved to Solution 2 for 3 min 
followed by 5 min in Solution 3. Finally the embryo was moved into a pre-equilibrated culture 
dish containing G2 Plus (VitroLife, 10132) supplemented with 20% human serum albumin 
(VitroLife, 10064). The equilibration process involved the exposure of the culture dish overnight 
in an undisturbed cell culture incubator (Sanyo MCO-5M) programmed for 6.2 % carbon dioxide 
and 5% oxygen. This setting allowed for the bicarbonate buffered culture medium to equilibrate 
to a pH of 7.27 ± 0.07. Warmed embryos were cultured for a period of 2 h followed by evaluation 
of morphology. Embryos were then placed in the center well of the transfer dish (Falcon 35307). 
The blastocysts at uterine embryo transfer was placed in the transfer catheter by myself and passed 
to a physician. The physician guided the catheter in the uterus, at which point I expelled the 
contents of the catheter, blastocyst(s) in medium, in the uterine cavity.  
 
 Terminology 
Single embryo transfer (SET) is defined as one blastocyst transferred to the uterus of the 
mother. Double embryo transfer (DET) is defined as two blastocysts simultaneously transferred to 
the mother’s uterus. Clinical pregnancy is defined as two positive serum beta human chorionic 
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gonadotropin (bHCG) values on 10 and 12 days post uterine embryo transfer (ET). With two 
established quantitative values, which arise from day 10 to day 12, the individual is considered to 
have positive chemical pregnancy outcome. Biochemical pregnancy is defined as an initial positive 
quantitative value on 10 days post ET and a subsequent decline of the value on day 12 post ET. 
Fetal Heart Beat (FHB) is defined as presence of fetal heart beat revealed by ultrasound at 5 weeks 
post uterine embryo transfer. Implantation rate is defined as the number of embryos with 
measurable FHB observed per blastocyst transferred in that category. Ongoing pregnancy rate is 
defined by the number of individuals that have at least one FHB observed per IVF treatment in 
that category. Miscarriage is defined by at least one FHB observed following a subsequent loss of 
pregnancy prior to 20 weeks of gestation.  
 
 Statistical Methods 
The distinct interaction of variables and their influence on IVF treatment outcome was 
found through the use generalized additive model (GAM) using linear regression and a 
permutation analysis with R software as part of the regression tree computational analysis (Huimin 
Liu 2008; Kuhn and Johnson 2013).  Final fitting of the model was determined with a random 
forest algorithm (see Chapter 2), a method which determines classification of variables is using a 
regression approach. Decision tree construction was performed using the evolutionary tree 
algorithm using R software to maximize discrimination between groups at each node of the 
decision tree with maximal homogeneity in each split rule resulting from subset of the predictors 
(Grubinger et al. 2014). The evolutionary tree utilized regression and coupled it with a Bayesian 
information criterion (Fan and Gray 2005).  
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4.3 Results 
 Outcome Characteristics by Group 
Primary evaluation of results by group yielded the highest clinical pregnancy rate success 
in group B (aCCH) for single embryo transfers (68.3%, n=28) and double embryo transfer (86.7%, 
n=13) categories (table 4.2). Overall ongoing pregnancy rate was also the highest in group B 
(66.1%, n=37). The overall miscarriage rate was lowest, again, in group B (9.8%, n=4). The overall 
chemical pregnancy and implantation rate were the highest in group B (aCGH) per embryo 
transferred (figure 4.2). The mean female age in the reference group consisted of a younger patient 
population (group A was 32.4 ± 3.7 years, B was 35.5 ± 4.1 years, group C was 35.1 ± 4.4 years  
and group D was 36.4 ± 3.5 years). 
Table 4.2. Comparison of pregnancy and implantation outcomes within groups 
 Group A Group B Group C Group D 
Parameter No PGS aCGH NGS SNP array 
# of treatments with SET 142 41 37 49 
# of treatments with DET 81 15 13 24 
Clinical pregnancy rate with SET % (n  59.8% (85) 68.3% (28) 51.4% (19) 67.3% (33) 
Clinical pregnancy rate with DET % (  66.7% (54) 86.7% (13) 53.8% (7) 70.8% (17) 
Overall clinical pregnancy rate % (n) 62.3% (139) 73.2%  (41) 52.0% (26) 68.5% (50) 
Overall implantation rate % (n) 49.5% (151) 63.4% (45) 50.8% (32) 56.7% (55) 
Overall ongoing pregnancy rate % (n) 55.6 %  (124  66.1% (37) 46.0% (23) 60.3% (44) 
Overall miscarriage rate % (n) 10.7% (15) 9.8% (4) 11.5% (3) 12% (6) 




Figure 4.2. Success rate measured in presence of heartbeat.  Comparison of mean occurrence of 
heartbeats + standard error (SE), detected across all groups by number of embryos transferred.   
 
 Importance of Female Age 
Permutation analysis of variables using Random Forest analysis (see Chapter 2) (Breiman 
2001) determined female age as the variable, with the largest contributions to outcome (P<0.01, 
Gini index=74.28). FHB observed post-treatment ranked as the next most important (P=0.02, Gini 
index=17.01), followed by chemical pregnancy (P<0.01, Gini index=16.17) and finally number of 
embryos transferred (P<0.01, Gini index=13.59) (Table 4.3). The weighted importance assessment 
established that all four variables were interacting to influence outcome in the form of embryo 
viability, with respect to reference or screening group. 
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Table 4.3. Permutation of interactive variables 
Variables 
Mean Decrease Gini 
Index* P value** 
Female age 74.28 0.01 
Fetal Heart Beats (FHB) 17.01 0.02 
Chemical pregnancy 16.17 0.01 
Number of embryos transferred 13.59 0.01 
*P values determined using Random Forest model. 
**Mean Decrease Gini Index is a measure of impurity in the node. A large value is representative of greater role of 
variable in partitioning data into defined classes. 
 
A decision tree was then formulated using these variables explaining the homogeneity in 
the data and describing the probabilities of IVF treatment outcomes (Figure 4.3). The first clear 
discrimination in the dataset was observed for individuals <34 years of age (node1). This age group 
had characteristics, which appear in the reference group with an average predictive probability of 
approximately 65%. Individuals in this age group did not benefit from the pre-implantation 
screening (n=186). 
 
Figure 4.3. Tree for screening effect prediction.  The terminal variables, determined by random 
forest, presented as graphs for predictive probability of an individual in that specific path of 
originating from one of the four groups. The variables of importance in creation of split rules are: 
age of female patient or oocyte source (Female age), number of embryos transferred , outcome 
expected as chemical pregnancy (Chemical  Pregnancy) , and  occurrence of beating fetal hearts 
observed (# Fetal Heart Beats). 
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Individuals 34-36 years of age had the highest average probability of having characteristics 
from the reference group based on a chemical pregnancy outcome of ~58% (nodes 4 and 5). 
Individuals in this class demonstrated a slight and equal benefit to any form of PGS technique with 
no differences observed among PGS techniques (aCGH, NGS or SNP array).  Individuals of 37-
38 years, benefited from any PGS techniques equally, without which pregnancy success was <20% 
(node 14, n=9). Single embryo transfer showed the highest rate of success with the least number 
of embryos transferred, resulting from aCGH screened euploid embryos with an average predictive 
probability of ~50% (n=24, node 10). Individuals >39 years benefited from PGS (nodes 17, 18 and 
19). The highest success of this group was achieved when euploid embryos were transferred using 
NGS (node 19) with the average predictive probability of ~65% (n=8).  
 
 Accuracy Determination of Random Forest Analysis for Screening Effect 
PGS groups were compared against the reference group to determine the accuracy and 
effect size of any final node on the random forest analysis. All terminal nodes in figure 4.3 predict 
decision results for all 4 groups. Therefore, the receiver operating curve analysis was performed 
for each of the PGS groups against the reference group. Any final node predicting that a PGS 
technique will yield in higher success than reference group has a higher success than chance alone 
(figure 4.4). 
• Group B (aCGH) has an area under the curve (AUC) of 0.70 indicating that any final 
node of the decision tree will result in 14% greater success than chance alone as the lower measure 
of success and 27% greater success than chance alone as its highest measure of success determined 
by 95% confidence intervals (0.64 – 0.77). 
• Group C (NGS) has an area under the curve (AUC) of 0.63 indicating that any final 
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node of the decision tree will result in 13% greater success than chance alone as the lower measure 
of success and 20% greater success than chance alone as its highest measure of success determined 
by 95% confidence intervals (0.57 – 0.70). 
• Group D (SNP array) has an area under the curve (AUC) of 0.69 indicating that any final 
node of the decision tree will result in 14% greater success than chance alone as the lower measure 
of success and 26% greater success than chance alone as its highest measure of success determined 
by 95% confidence intervals (0.57 – 0.70). 
Figure 4.4. ROC analyses for screening effect. True 
positive rate (sensitivity) is plotted against the false 
positive rate (1-specificity). Each of the screening 
groups was compared against the reference groups for 
the area under the curve (AUC) using ROC analysis. 
Confidence intervals (95%) were determined using 
bootstrap CI to determine the effect size that takes 
specificity and sensitivity jointly into account 
demonstrating that the prediction model will results are 




Each screening group was expected to reduce 
the occurrence of miscarriages or spontaneous 
abortions with the use of euploid embryos (Handyside 
2013; Gleicher and Orvieto 2017; Dahdouh et al. 
2015). The results of the present study differ from 
previous claims that the utilization of PGS improves 
IVF outcomes while lowering miscarriages (Keltz et 
al. 2013). In the present study, no significant 
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improvement was observed in the reduction of miscarriages compared to the reference group, a 
finding in agreement with other studies in the literature (Gleicher et al. 2014; Gleicher et al. 2017). 
Although aneuploidy of whole chromosomes is prevalent and a leading cause of spontaneous 
abortions, it may be inaccurate to report segmental deletions or duplications of chromosomes in 
embryos as aneuploid. The evidence and understanding of embryology and mechanisms of self 
correction of DNA errors in early embryos is still not well understood.  
Next generation sequencing has shed light on the importance of detecting aneuploidy at a 
level, which includes mosaicism as well as small segmental deletions or duplications of 
chromosomes in preimplantation embryos. This technology has proven to be most advantageous 
for women >39 years when rate of DNA copy error is the highest (figure 4.3, >39 year node). Yet, 
our hypothesis that accuracy of SNP arrays in determining euploidy of blastocysts yield the highest 
pregnancy outcome is rejected. Based on the data from the current study, a comparison of the three 
methods of PGS demonstrated NGS to be most efficient and beneficial in determination of 
embryonic ploidy and genomic errors specifically for individuals >37 years. Although SNP micro-
array and aCGH are comparable for accuracy in terms of euploid embryos resulting in pregnancy, 
the rate of successful pregnancies decreases with advancing maternal age compared to NGS.  
Based on the findings of this study, it is recommended that: 
1) NGS be offered to individuals presenting with infertility of age >37 years 
2) Younger individuals should be counseled and advised that NGS does not demonstrate 
statistically higher pregnancy success compared to aCGH and SNP microarray.  
Mosaicism went unreported with both array Comparative Genomic Hybridization (aCGH) 
and single nucleotide polymorphism array (SNP array) techniques. As a result, greater than 
expected rate of biochemical pregnancies was observed for transferal of reported euploid embryos 
(which may have been mosaic). A higher rate of biochemical pregnancies is associated with the 
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transfer of a mosaic embryo when compared to the transfer of embryos that were euploid (Lledó 
et al. 2017; Daughtry and Chavez 2016). 1-2% of all preimplantation embryos across all maternal 
ages demonstrate mosaicism (Capalbo et al. 2017). As a result, since a minority of embryos are 
affected by mosaicism (<3%), NGS and technologies that are capable of detecting mosaic embryos 
will result in marginal improvement in clinical pregnancy outcome. Capalbo et al. (2017) failed to 
distinguish the variability in the rate of mosaic embryos due to maternal age. As demonstrated by 
the current study, NGS is most beneficial when maternal age is >39 years. This evidence suggests 
that mosaic embryos may be more prevalent in the older maternal population resulting in higher 
rates of spontaneous abortions. Identification of segmental chromosomal mosaicism and partial 
chromosomal mosaic cells lines in these embryos is now possible due to NGS technology, making 
it an asset in embryo selection for pregnancy with IVF. 
In direct contradiction to the study of Capalbo et al. (2017), which showed 1-2% prevalence 
of mosaicism in preimplantation embryos, greater mosaicism rate is observed in a significant 
proportion of biopsies analyzed by NGS (Munné and Wells 2017). Furthermore, Munné and Wells 
identify a positive correlation of maternal age and rate of embryonic mosaicism. Aneuploidy in 
embryos of advanced maternal age individuals as the product of non-disjunction during meiosis is 
more likely. Aneuploidy is also explained by partial monosomies or trisomies and segmental loss 
of chromosomal content.  Munné and Wells (2017) confirmed an increase in miscarriage rate from 
mosaic embryos compared to pregnancies achieved with euploid embryo transfers. In the past, the 
use of aCGH yielded the highest success in pregnancy outcome when a euploid embryo was 
transplanted in individuals of <35 years, but was significantly less effective in the older maternal 
age groups. Single nucleotide polymorphism array demonstrated a higher rate of success compared 
to aCGH due to greater in depth sequencing method. SNP also demonstrated a decrease in rate of 
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success with advancing maternal age. NGS identifies errors beyond whole chromosome deletions 
or duplications and large segmental deletions or duplications, it identifies mosaicism, thereby, 
reducing the rate of spontaneous abortions and ultimately increasing the rate of sustainable 
pregnancy in individuals with advanced maternal age.  
 
4.5 Conclusion 
Evidence from secondary analysis with interactions from the current study has established 
that the use of PGS for individuals of <34 years of age has no benefit. Patients should be counseled 
appropriately to minimize unnecessary biopsy procedures on embryos and to minimize patient 
financial burden. Furthermore, the results of the current study demonstrate no significant 
difference in pregnancy outcome of individuals of maternal age between 35-37 years when 
compared across the PGS techniques (aCGH, SNP array and NGS). Individuals should be 
counseled appropriately and a decision, of which PGS techniques to utilize should include 
procedural costs. Other factors in patient diagnosis (i.e., DOR) should be reviewed to determine if 
PGS is beneficial. A final conclusion is that NGS should be used for individuals of advanced 
maternal age (>38 years) to maximize success outcome of this sub-population. Future studies, 
which include specific rate of mosaicism of embryos by maternal age and the error rate in 
misdiagnosis or false positive detection of mosaic lines in embryonic biopsied samples by maternal 




FOLLICLE STIMULATING HORMONE AND ANTIMÜLLERIAN HORMONE AS 
INDICATORS OF EMBRYONIC DEVELOPMENT 
5.1 Introduction 
The condition of diminished ovarian reserve (DOR) is characterized by poor fertility 
outcomes and currently presents as a major challenge in reproductive medicine, particularly in 
vitro fertilization (IVF) (Cohen et al. 2015; Atasever et al. 2016).  Women are diagnosed with 
DOR if they demonstrate at least one of the following:  
• high follicle stimulating hormone (FSH) levels when not in the follicular phase  
• low antral follicle counts  
• low anti-müllerian hormone (AMH)  
A woman in her reproductive years has good prognosis when her FSH is between 3.1-7.9 
mIU/ml and her AMH is ≥1 ng/ml (Atasever et al. 2016; Muasher et al. 1988; Abdalla 2004). 
AMH is used to assess the remaining ovarian reserve as well as predictor of response to controlled 
hyperstimulation of the ovaries during IVF treatment (Broer et al. 2011; Tal et al. 2015; de Vet et 
al. 2002).  
Women with elevated basal FSH are reported to still achieve reasonable pregnancy rates, 
but few studies report correlation with blastocysts development (Safdarian et al. 2012; Broekmans 
et al.  2009; Levi et al. 2001; Esposito et al. 2002). The purpose of the current study is to understand 
the interaction between the number of mature follicles at trigger, AMH and basal FSH values with 
blastocysts development in DOR and POF patients as compared to good prognosis patients. The 
current study examines the correlation between diagnostic findings of basal FSH and AMH values 
and their predictive value in embryo development. Diagnostic values of AMH/basal FSH can be 
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resourceful in determining the optimal simulation protocol and identification of individuals who 
will not benefit from IVF due to poor prognosis. I hypothesize that individuals who have an AMH 
of <1 ng/ml and a basal FSH greater than 8 mIU/ml have significantly lower percentage of high 
quality embryos compared to patients that have values considered normal for fertility. 
 
5.2 Material and Methods 
This study is prospective (data collected forward in time) analysis of frozen embryo 
transfer treatments performed at a single site, Dallas IVF, referred to as “the Center6.” The 
observational data included IVF treatments over a six month period (January 1, 2015 to June 31, 
2015). The data for treatments included in this study were retrieved using an electronic database 
management system (eIVF, USA), in which the data was de-identified to remain in compliance 
with Health Information Portability and Accountability Act (HIPAA).  
 
 Study Population 
All patients that underwent IVF treatment were included in the study regardless of age or 
prognosis. The most recent basal FSH level (samples drawn on days 2-4 of menses) was obtained 
prior to initiation of treatment. Patients were treated with either of the following protocols: 
• GnRH (Gonadotropin releasing hormone ) antagonist: This protocol includes the use 
of medication such as Ganarelix for the suppression of luteinizing hormone (LH) surge and 
ovulation by blocking the secretion pituitary gonadotropins, supplemented by medication 
containing follicle stimulating hormone (FSH) to stimulate follicular growth and development and 
                                                 
6 Dallas IVF is a registered member of the American Society of Reproductive Medicine and a Society of Assisted 
Reproductive Technology. The facility is accredited by College of American Pathology (CAP), Clinical Laboratory 
Improvement Amendments (CLIA) and is registered with the Food and Drug Administration (FDA). 
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a medication containing human chorionic gonadotropin to induce final maturation of oocytes 
within follicles prior to ovarian retrieval (Hebisha et al.2017; Lai et al. 2013). 
• Long agonist protocol: This protocol includes the use of a pituitary down-regulation 
during the luteal peak period (7-10 days prior to the start of the menstrual cycle) to prevent 
premature luteinization and ovulation (Siristatidis et al. 2015). After this initial period, medications 
containing FSH are added to promote follicular development. Finally HCG medication is 
administered for final oocyte maturity prior to retrieval (Lai et al. 2013; Surrey 2007). 
All patients who underwent ovarian stimulation and subsequent IVF culture were included 
in the study. 
 
 Hormone Assays and Follicular Measurements 
Endocrine assays for serum FSH, AMH and estradiol concentrations were performed by a 
reference laboratory (LapCorp) using liquid chromatography/tandem mass spectrometry (LC/MS-
MS) (Ketha et al. 2014; Koal et al. 2012). Measurements of follicular development were performed 
at the Center by a sonographer certified by American Registry for Diagnostic Medical Sonography 
(ARDMS). Follicle growth was measured in millimeters and was a mean diameter per follicle. 
Calculations of the mean were provided by the ultrasound software. 
 
 Treatment Protocol 
Controlled ovarian stimulation was carried out for all patients using either the down 
regulated agonist long protocol or the antagonist protocols, as previously described. A transvaginal 
scan was performed prior to stimulation to ensure ovaries were free of cysts. Both protocols 
incorporated either recombinant FSH and hMG (human menopausal gonadotropins) or urinary 
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FSH. For the long protocol, down regulation of patients was obtained through leuprolide 
(Lupron®) administration beginning mid-luteal phase. For the antagonist protocol GnRH 
(gonadotropin releasing hormone) was administered when the lead follicle reached 15mm in 
diameter or the latest by day 7 of stimulation. When a majority of the follicles developed between 
16-24mm in diameter and serum estradiol levels were rising appropriately to reflect oocyte 
maturation, the patients were then triggered for oocyte retrieval by the administration of 10,000 
IU of human chorionic gonadotropin (HCG) for either protocol or Lupron trigger with the 
antagonist protocol.  Oocyte aspiration was performed under ultrasound guidance between 36-38h 
post trigger administration.  Insemination of oocytes and culture of embryos was performed over 
a six day period following transvaginal oocyte retrieval (TVOR). Embryos were graded using the 
SART grading system (Heitmann et al. 2013).  
 
 Definition of Outcome 
The following definitions apply to the outcomes measured in this study. 
• Minimum AMH is defined as the lowest measured anti-müllerian hormone level (ng/ml) 
prior to the start of IVF treatment.  
• Maximum FSH is defined as the highest follicle stimulating hormone level (mIU/ml) 
measured on menstrual IVF treatment day 3.  
• Mature follicle is defined as a follicle which measures >16mm in diameter. 
• Estradiol (E2) at trigger is defined as the highest measured serum estradiol level 
(pg/ml) prior to trigger medication administration. 
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• Total IU medication is defined as the total international units of gonadotropins 
(FSH/LH) administered over the length of the follicular stimulation IVF treatment. Day of trigger 
is defined as the stimulation day upon which either HCG or Lupron® were administered.  
• High quality blastocysts are defined as the number of blastocysts that were usable for 
cryopreservation or uterine transfer.  
• Success is defined as >40% of fertilized oocytes developed into high quality blastocysts 
per IVF treatment. 
 
 Data Analysis 
The distinct interaction of variables and their influence on IVF treatment outcome was 
analyzed through the use of a generalized linear model (GLM) employing logistic regression and 
survival analysis with R software (Huimin Liu 2008; Kuhn and Johnson 2013).  Final fitting of the 
model was determined through the use of random forest algorithm, a method which determines 
classification of variables using a regression approach. Decision tree construction was performed 
using the evolutionary tree algorithm using R software to maximize discrimination between groups 
at each node of the decision tree with maximal homogeneity in each split rule resulting from subset 
of the predictors (Grubinger et al. 2014). The evolutionary tree utilized regression and coupled it 
with a Bayesian information criterion (Fan and Gray 2005). 
 
5.3 Results 
Data evaluated for individuals who produced >12 mature follicles was compared to 
individuals who produced <12 mature follicles at trigger. The latter group consists of individuals 
presenting with diminished ovarian reserve or preliminary ovarian failure. Total IUs of medication 
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were approximately 1000 international units (IU) more per IVF treatment compared to the group 
producing more mature follicles (Table 5.1). Despite the larger quantity of drugs, the estradiol at 
trigger were observed to be approximately 1700 pg/ml lower than individuals who produced >12 
mature follicles at trigger.  
The generalized linear model determined minimum AMH, total IU medication, number of 
mature follicles at trigger and E2 at trigger as significant actionable contributors in optimizing 
blastocyst development per IVF treatment. A median percentage of 40% fertilized oocytes 
developed into high quality blastocysts was 40% (table 5.1). Evtree analysis was performed to 
optimize blastocyst development per IVF treatment to discriminate outcome over the median. The 
analysis demonstrated that individuals whose E2 at trigger was <1584 pg/ml had a 80% probability 
of >40% blastocyst development success (n=7, node 2) (Figure 5.1). When E2 at trigger was >1584 
pg/ml, the number of mature follicles at trigger <12 and total IU medication <3025 resulted in 90% 
blastocyst development success (n=10, node 5). Total IU medication could be above 3025 IU for 
this group if E2 at trigger was <2748 pg/ml and minimum AMH was <1.783 ng/ml for 80% 
blastocyst development success (n=8, node 11). Higher minimum AMH and E2 at trigger for this 
group resulted in <15% success (nodes 9, 10). When E2 at trigger was >1584 pg/ml and >12 mature 
follicles were present, success was improved by administering <3025 total IU medication with 
trigger administered by the 10th day of stimulation (node 13). If the E2 at trigger was <3056 pg/ml, 
70% success was observed (n=7, node 14). E2 at trigger could exceed 3056 pg/ml only if maximum 
FSH was >6.5 mIU/ml resulting in 85% success (n=12, node 17).  
96 
Table 5.1. Comparison of treatments reflected by number of mature follicles at trigger 
 > 12 mature follicles  <12 mature follicles 
Parameter n=61 n=45 
Female age (years) 34.4 ± 0.6 35.9 ± 0.7 
Male partner age (years) 37.9 ± 0.9 38.6 ± 0.9 
Total IUs of gonadotropins/IVF 
treatment 3070.1 ± 191.0 4110.8 ± 138.6 
Estradiol level at trigger (pg/ml) 4547.8 ± 257.6 2821.6 ± 227.9 
Max basal FSH (mIU/ml) 6.6 ± 0.4 7.8 ± 0.2 
Min AMH (ng/ml) 5.4 ± 0.5 3.2 ± 0.7 
# Oocytes retrieved 22.9 ± 1.3 14.9 ± 1.4 
# Oocytes normally fertilized 14.2 ± 0.9 8.8 ± 1.0 
# High quality blasts 5.4 ± 0.4 3.3 ± 0.4 
%High quality blasts 38.9 ± 3.5 38.9 ± 2.4 
Mean values are reported ± std. error 
 
 
Figure 5.1. Tree for blastocyst optimization. Final graphed nodes depict successful treatments 
(>40% blastocyst development, dark shading). Failed treatments (<40% blastocyst development) 
are shaded light. Values on the right of each bar represent the percent of successful treatments. 
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Success was over 90% when E2 at trigger was >1564pg/ml, >12 mature follicles at trigger, 
>3325 IU medication and minimum AMH of <3.156 ng/ml (n=9, node 20). The accuracy of the 
decision tree was calculated at 86.5 percent with an error rate of 13.5%. The receiver operating 
characteristic (ROC) curve area is roughly .87 (Figure 5.2) (see Chapter 2) (Robin et al. 2011) . 
Confidence intervals of 0.7996 - 0.9312 indicate that any final node on the model will yield 29% 
greater success than chance alone at the lowest predictive accuracy and 43% greater success than 
chance alone at its highest predictive accuracy. 
 
Figure 5.2. Receiver operating characteristic curve: blastocyst optimization model. True positive 
rate (sensitivity) is plotted against the false positive rate (1-specificity). The dark areas are the 95% 
confidence intervals.  
 
5.4 Discussion 
Basal FSH level and minimum AMH levels are routinely used as indicators of patient’s 
pregnancy outcome or indication of IVF treatment prognosis. Yet, there remains a gap in 
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understanding how these values correlate with blastocyst developmental potential. Elevated basal 
FSH levels have been associated with a reduced overall live birth rate compared to individuals 
with normal levels (Abdalla and Thum 2004; Butts et al. 2013). I suggest that the live birth rate 
can be improved if the overall percent blastocyst production per IVF treatment is optimized by 
utilizing the decision tree of the current study. Surprisingly, individuals with good ovarian reserve 
(AMH >3.2 ng/ml) have an overall decreased blastocyst development rate compared to individuals 
with lower reserve. Larger numbers of follicles developing simultaneously may demonstrate 
slowed growth on ovarian scans since the gonadotropin dose is shared between follicles. As a 
result, gonadotropin doses are increased by clinicians to promote growth, which substantially 
relegates overall blastocyst development. Individuals with a poor prognosis due to diminished 
ovarian reserve (DOR) or preliminary ovarian failure (POF) shown here to have <12 mature 
follicles at trigger (Figure 5.2, node 3) demonstrate greater success when gonadotropins are <3025 
total IUs and estradiol at trigger is under 2750 pg/ml. The correlation between the rate of follicle 
development and total IU of gonadotropins administered during stimulation produced a lowered 
rate of blastocyst developmental success when the patient was over-exposed to gonadotropins 
(Figure 5.1, node 21), as demonstrated by 0/11 successful treatments in this study. 
I reject the hypothesis that patients who have an AMH of <1 ng/ml and a basal FSH greater 
than 8 mIU/ml have significantly lower percentage of high quality embryos compared to patients 
that have values considered normal for fertility. Instead, the current study indicates that individuals 
with elevated FSH had >12 mature follicles at trigger and over 80% of treatments were successful 
when total medication doses are <3325 IU. Thus elevated FSH levels do not indicate poor ovarian 
reserve or lower success (Table 5.1). I found that AMH values are reliable indicators of blastocyst 
developmental potential compared to basal FSH values. Patients presenting with decreased AMH 
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levels generally have <12 mature follicles at trigger and over 80% of treatments were successful 
when estradiol at trigger was less than 2750 pg/ml even when total IU of medication exceeded 
3000 IU. I confirmed that patients with DOR, POF or poor prognosis overall exhibit overall a high 
rate of good quality blastocyst development per IVF treatment, which positively correlates with 
increasing levels of gonadotropins contrary to individuals with a higher number of mature follicles 
at trigger.  
 
5.5 Conclusion 
IVF treatments for patients that present with infertility due to DOR or POF, if managed 
appropriately, can produce higher rates of usable blastocyst production per IVF treatment, thus 
increasing rate of blastocyst developmental success. A greater number of high quality blastocysts 
increase the rate of pregnancy outcome per IVF treatment. This results in lower costs of treatments 
for the patient and lower emotional burden. Future studies are recommended with larger IVF 





EFFECTS OF CULTURE pH AND PARTIAL PRESSURES OF OXYGEN AND CARBON 
DIOXIDE ON BLASTOCYST DEVELOPMENT 
6.1 Introduction 
One of the primary responsibilities of embryologists who perform human in vitro 
fertilization is optimization of embryo culture conditions to provide optimal embryonic 
development (and ultimately maximization of live births). Although pregnancy and live birth are 
the end goal of in vitro fertilization, our primary concern and focus was on the percent of high 
quality blastocyst production per treatment for optimization of all aspects (i.e., lessen patient 
financial burden, maximize high quality blastocyst development per treatment to satisfy patients’ 
family building needs) associated with IVF especially for patients with diminished ovarian reserve 
or preliminary ovarian failure. 
The primary environment of developing embryos in vitro consists of culture medium and 
its physio-chemical characteristics regulated by incubation. Culture conditions greatly influence 
embryonic cellular metabolism as well as gene expression in different species of mammalian 
embryos (Bauer et al. 2010; Gardner et al. 2013; Giritharan et al. 2012; de Los Santos et al. 2015).  
Optimal culture, in part, is a balance of pH and partial pressures of carbon dioxide (pCO2) and 
oxygen (pO2). The pH experienced by the embryos is a measure of hydrogen ion concentration, 
formed from the reaction between sodium bicarbonate in the medium and CO2 gas in the incubator 
chamber. The pH of the bicarbonate buffed medium rises as pCO2 in the incubator decreases. 
Maintenance of medium pH within acceptable ranges is critical in providing optimal medium 
nutrient status such as essential amino acids, hyaluronan, proteins and  lipoic acid (anti-oxidant) 
found in the bicarbonate buffered culture medium (Gardner and Kelley 2017; Swain 2010; Sifer 
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et al. 2009). Variability in these conditions may lead to improper nutrient status in the medium, 
which negatively impacts metabolism of the embryo and its ability to express parts of the genome 
on time to maintain optimal development. Culture medium is held close to physiological 
conditions for pH and partial pressures of oxygen and carbon dioxide, with typical incubation 
levels being 6.2% ±0.3 CO2 and 5.0% ±0.2 O2. Normal ranges for pressure of dissolved gasses in 
IVF culture medium, when incubator settings are 6.2% CO2 and 5.0% O2, are as follows (according 
to the culture media manufacturer, iStat blood gas analyzer guide and the Center’s protocol 
manual): 
• pO2 83-108mmH 
• pCO2 32-40 mmHg  
• pH 7.20 to 7.34 
If pH measures within normal range, pCO2 and pO2 ranges may be expanded by 10% according to 
manufacturer’s recommendations.  
Intriguingly, a lower rate of high quality blastocysts is observed for embryos in culture 
from one patient compared to another using the same medium batch, despite this emphasis on 
constancy of conditions. This difference in overall rate of development may be due to subtle, yet 
important environmental conditions that can be explained and identified with quality assurance 
(QA) studies. Commercially produced culture medium is accompanied by certification of analysis 
(CoA) documenting that any given batch of media has undergone a robust QA study with the 
manufacturer. Additionally, prepared medium is often convenient for use and storage. Despite the 
CoA, it is critical to perform additional inter-laboratory QA assessment and quality control (QC) 
study to verify that the manufacturer’s results are reproducible and results produced onsite are 
within the allowable ranges for pH, partial pressures of pO2 and pCO2. Additionally, blastocyst 
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formation rate per batch may also be analyzed to ensure quality within the IVF laboratory. This 
aids in a timely identification and, if needed, calibration of faulty equipment or internal 
adjustments of gas levels per incubator. Extensive recommendations are available on medium pH 
(Swain et al. 2016; Wale and Gardner 2016; Gardner and Kelley 2017).  
Despite an industry focus on quality assurance, implications -if any- of small variations in 
level of pCO2 and pO2 in the medium to embryo development have not been established.  
Consequently, my study has analyzed how the rate of blastocyst development is influenced by 
variation in pH, pCO2 and pO2 during culture. The goal was to identify whether currently 
acceptable ranges of culture pH, pCO2 and pO2 need to be further narrowed to optimize IVF 
treatment outcome and/or if there is an “incubator effect” influencing the percentage of high 
quality blastocysts. The purpose of this study is to understand how embryonic development is 
influenced by culture conditions associated with subtle variations of pH and partial pressures of 
oxygen and carbon dioxide in the medium. I hypothesized that subtle variation in incubator 
conditions can lead to poor blastocyst development. 
 
6.2 Material and Methods 
 Location and Data Management and Study Population 
This study is a prospective analysis of IVF at a single site, Dallas IVF, referred to as “the 
Center7.” The data for treatments included in this study were collected using an excel spreadsheet 
with manual data entry for culture conditions as well as electronic database management system 
(eIVF, USA). Data were de-identified to remain in compliance with Health Information Portability 
                                                 
7 Dallas IVF is a registered member of the American Society of Reproductive Medicine and a Society of Assisted 
Reproductive Technology. The facility is accredited by College of American Pathology (CAP), Clinical Laboratory 
Improvement Amendments (CLIA) and is registered with the Food and Drug Administration (FDA). 
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and Accountability Act (HIPAA). All IVF treatments performed from November 1, 2016 to Feb 
28, 2017 at the Center were included in the study with the exception of oocyte and zygote warming 
(previously vitrified) treatments. A total of 42 treatments included in the study were initially 
organized into two groups for primary analysis of treatment characteristics with <12 oocytes 
retrieved designated group A(1˚) (n=27) and >12 oocytes retrieved group B(1˚) (n=15) based on 
statistical analysis and findings from Hariton et al. (2017) and Zhou et al. (2017). Group A, 
included patients presenting with diminished ovarian reserve or preliminary ovarian failure where 
as group B, included all other patients.  The groups were subsequently organized to examine 
treatment characteristics with <14 oocytes retrieved Group A(2˚) (n=32,) and >14 oocytes group 
B(2˚) (n=10,) as it was determined by the Evtree analysis as significant in outcome determination. 
 
 Laboratory Environment and Testing 
Sanyo incubators (Model-MCO-5M) were measured daily for chamber gas levels to ensure 
proper calibration of set values (6.2±0.3% for CO2 and 5.0±0.2% for O2). Chamber gas was 
measured daily using a G100 gas analyzer, for which a calibration curve was validated (Chapter 
3,) (Viasensor). Embryo culture dishes were prepared using 35mm Petri dishes (Thermo 
Scientific™ 153066). Seven- 40 μl drops of culture medium, G1TM Plus (VitroLife, 10128) for the 
first three days then G2TM Plus for days 3-6 (VitroLife, 10132) were placed in the dish and overlaid 
with 4ml of culture oil (VitroLife, 10029). The dishes were placed in the incubator for equilibration 
for a minimum of 12 hours (see Chapter 1). Each batch of culture medium was tested for pH, pCO2 
and pO2 using the iSTAT1 handheld (Abbott) post-equilibration. A sample of the equilibrated 
medium (0.1 ml) was drawn up from the culture dish via syringe and was injected into the iSTAT 
cartridge for testing. Results for each batch in each incubator were collected once per day over a 
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period of three consecutive days. The mean values were calculated for pH, pCO2 and pO2 per 
incubator, per batch. Embryos were cultured in sequential medium (VitroLife, G Series TM) in one 
of three designated incubators assigned based on incubator availability. Embryos were graded 
according to the SART grading system (Heitmann et al. 2013) using an inverted microscope 
(Olympus IX70). 
 
 Definition of Outcome and Terminology 
Good quality day 3 embryos were defined as embryos that have cleaved into 6-8 cells, had 
<10% cellular fragmentation and exhibit moderate to perfect symmetry according to SART 
grading criteria (see Chapter 1). High quality blastocysts were defined as embryos on days 5 and 
6, which exhibited an expanded zona pellucida, a compacted inner cell mass and a symmetrical 
cell organization in the trophectoderm. Success was defined as >60% of fertilized oocytes 
developing into high quality blastocysts for the primary Evtree analysis and >65% fertilized 
oocytes developing to high quality day 3 embryos per treatment for the secondary Evtree analysis.  
 
 Data Analysis 
Principal components analysis was performed with SigmaPlot software. All data were 
reported as mean ±1 standard error. Additionally, decision tree construction was performed using 
the evolutionary tree algorithm (Evtree) using R software (Grubinger et al. 2014; Fan and Gray 
2005) (see Chapter 2). The receiver operating characteristic (ROC) curve analysis, which 
illustrates Evtree’s diagnostic ability as the discrimination threshold is varied for the statistical 
computation (Robin et al. 2011), was performed. The ROC curve calculates the rate of sensitivity 
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given the optimal specificity. With both specificity and sensitivity computed, an overall accuracy 
of the model was calculated. 
 
6.3 Results 
 Culture Medium Conditions 
Daily chamber gases measurements had a mean deviation from set-point of 0.0 △CO2 for 
all 3 incubators, 0.0 △O2 for incubators #1 and #2 and 0.1 △O2 for incubator #3. Culture media 
conditions were measured by the i-Stat. Incubator #2 had within-range values for G1 Plus and G2 
Plus for pH, pCO2 and O2. Both Incubators #1 and #3 had out-of-range measurements for both G1 
Plus and G2 Plus (table 6.1). Despite this consistency in measured chamber gas concentrations, 
incubator #3 resulted in out-of-range values for pH, pCO2 and O2 for all batches of both sequential 
medium as well as pH and pCO2 for the primary batch of G1 Plus (table 6.1). Additionally, pCO2 
in solutions (G1 Plus and G2 Plus) were measured out-of-range in incubators #1 and #3 but within 
range in incubator #2. 
 
 Characteristics of the Study Population 
6.3.2.1 Primary Grouping  
Initial analysis of the data was performed by evaluating the data in two categories: Group 
A(1˚) (<12 oocytes, n= 27) and group B(1˚) (>12 oocytes, n=15), in which group A(1˚) included 
DOR and POF patients who are expected to have fewer blastocysts compared to group B(1˚) due 
to fewer oocytes retrieved. As expected, the number of oocytes inseminated, number of oocytes 
normally fertilized, number of good quality embryos on day 3 of development and the number of 
high quality blastocysts on day 5 were all higher per treatment in group B(1˚) (figure 6.1). 
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Interestingly, mean number of normally fertilized oocytes in group A was 4.3 +0.4, of which a 
mean number of 2.4 ±0.3 embryos developed into good quality blastocysts (56% success per 
treatment). This comprised a higher success than group B(1˚), which had 8.9 +1.1 normally 
fertilized oocytes, of which only 4.3 +1.1 embryos developed into high quality blastocysts (48% 
success per treatment), thus lower rate of high quality blastocysts per treatment despite greater 
number of oocytes initially. 
 
Figure 6.1. Treatment characteristics. Data demonstrate outcomes observed for patients in group 
A (1˚: <12 oocytes retrieved, 2˚: <14 oocytes retrieved) compared to group B(1˚: >12 oocytes 
retrieved, 2˚: >14oocytes retrieved.  
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6.3.2.2 Secondary Grouping  
Decision tree results (discussed next) were conducted to understand the relationship 
between variations in population characteristics based on oocyte number. Based on this analysis, 
reorganization of the groups was conducted to include all treatments with <14 oocytes in group 
A(2˚) and >14 oocytes retrieved in group B(2˚). The number of high quality blastocysts in group 
A(2˚) was 2.9 ±0.3 (49%) compared to 6.4±1.3 (63%) in group B(2˚). These results demonstrated 
an expected rate of development given the patients that recruited a higher number of oocytes per 
treatment were generally good responders to gonadotropin treatment (see Chapter 1) and had a 
larger percent of high quality blastocysts per treatment. The age of patients in group A(2˚) (<14 
oocytes) was 36.4 ±0.9 years compared to 35.5 ±1.8 years in group B(2˚) (>14 oocytes) (figure 
6.2). 
 
Figure 6.2. Age distribution within groups.   Group A (1˚: <12 oocytes retrieved, 2˚: <14 oocytes 
retrieved) compared to group B (1˚: >12 oocytes retrieved, 2˚: >14oocytes retrieved. There was no 
significant difference of patient age in the various treatment groups. 
 
To identify the factors influencing the variation in rate of blastocyst development per 
treatment, the data were analyzed with Evtree using R software, which we now discuss. 
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 Culture Effects on Blastocyst and Cleavage Embryo Development 
6.3.3.1 Blastocyst Development Outcome 
The success for all treatments in the study was measured with percentage of high quality 
blastocysts development as the final outcome measure imputed into the Evtree primary decision 
tree analysis. Sixty % (median) of normally fertilized oocytes had developed into high quality 
blastocysts. In light of this, we defined success as all treatments that had an outcome over the 
median (>60% high quality blastocyst development). Accordingly, the number of normally 
fertilized oocytes, patient age, incubator number, pH (G1 and G2 Plus), pCO2 (G1 and G2 Plus) 
and pO2 (G1 Plus) were all rejected as factors influencing blastocyst success (figure 6.3).  
 
Figure 6.3. Decision tree for high quality blastocysts development. Decision tree for high quality 
blastocyst development, a prediction model determined by Evtree. Final graphed nodes depict 
successful treatments (>60% blastocyst development, dark shading in stacked bars). Failed 
treatments (<60% blastocyst development) are in white shading in stacked bars. Values on the left 
of each bar represent the percent of successful treatments. 
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The pO2 for the G2 Plus medium was the single contributing actionable variable that 
influenced blastocyst development. When pO2 was <69 mmHg, there was ~70% success (Figure 
6.3, node 2, n=9). When pO2 was 69-89 mmHg coupled with <60% good quality embryos on day 
3, treatment outcome resulted in poor blastocyst development, <10% success (node 5, n=11). 
Conversely, treatments that demonstrated >60% of good quality embryo on day 3 exhibited >90% 
success (node 6, n=12). This large difference in outcome was highly reliant on day 3 embryo 
development in this decision arm with a large variation in success (10% vs. 90%, node 11 and 12).  
 
6.3.3.2 Day 3 –Cleavage Stage- Embryo Development Outcome 
A second decision tree analysis was computed to understand and identify factors that 
influence cleavage stage (day 3) quality. This time, the success for all treatments in the study was 
measured with percentage of good quality day 3 embryo development as the final outcome 
measure in the secondary decision tree analysis. Sixty-five % (median) of normally fertilized 
oocytes developed into good quality day 3 embryos. In light of this, we defined success for this 
analysis as all treatments, which had an outcome over the median (>65% good quality day 3 
embryo development). All variables associated with development beyond day 3 were not included 
in the analysis (G2 Plus medium parameters and % blastocyst development) because these 
parameters were a part of later embryo development and not associated with outcome of day 3 
embryo quality. This model rejected pH (G1 Plus), pO2 (G1 Plus) and number of normally 
fertilized oocytes as factors influencing embryo success (figure 6.4).  Interestingly, embryos from 
females <31.6 years resulted in 30% success for day 3 good quality embryo development (node 2, 
n=7). However, embryos from females >31.6 years and ≥14 oocytes at retrieval resulted in an 85% 
success (node 9, n=7).  
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Figure 6.4. Decision tree for good quality day 3 embryo development. Determined by Evtree, final 
graphed nodes depict successful treatments (>65% day 3 good quality embryo development, dark 
shading). Failed treatments (<65% day 3 good quality embryo development) are white. Values on 
the left of each bar represent the percent of successful treatments. 
 
The medium pCO2 significantly affected the outcome of day 3 embryo development from 
patients >31.6 years with <14 oocytes retrieved. Where pCO2 was >30.0 mmHg, there was an 80% 
success for incubators #1 and #2 (node 7, n=12). However, embryos in incubator #3 had only 25% 
success (node 8, n=9). This identified a variation in rate of blastocysts development for embryos 
in incubator #3 specifically for oocytes retrieved from patients in Group A(2˚), irrespective of 
medium batch. Lastly, for day 3 embryos from patients >31.6 years who had ≥14 oocytes retrieved, 
Group B(2˚) had 80% success independent of the incubator number, pH, pCO2 or pO2 observed. 
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6.3.3.3 Accuracy Determination of Evtree Analyses 
The accuracy of the primary Evtree analysis for blastocysts, determined by the receiver 
operating characteristic curve (ROC) (see Chapter 2), was 79% with an error rate of 21% for 
decision tree of blastocyst development (figure 6.5A). The ROC curve had an area under the curve 
(AUC) of 0.76 with 95% confidence interval (CI) of 0.63-0.88, indicating that any final node of 
the decision tree will result in 13% greater success than chance alone as the lowest measure and 
up to 38% greater success than chance alone at 
its highest success. The accuracy of the 
secondary Evtree for day 3 embryo 
development was 76% with an error rate of 24% 
(figure 6.5B). The ROC curve had an area under 
the curve (AUC) of 0.76 with 95% confidence 
interval (CI) of 0.63-0.89. This indicates that a 
final node on the decision tree will result in 13% 
greater success than chance alone as the lowest 
measure and up to 39% greater success than 
chance alone at its highest success. 
Figure 6.5. Receiver operating characteristic 
curve: blastocyst and embryo development. 
ROC Analyses of the Evtree Models for Embryo 
Success. True positive rate (sensitivity) is 
plotted against the false positive rate (1-
specificity). The dark areas are the 95% 
confidence intervals. (A) Blastocyst 
development as final measure of success, (B) 




 Patient Impact of Fewer Blastocysts per Treatment  
Pregnancy and live birth outcomes are the standard measure of success, in which any IVF 
treatment resulting in a pregnancy and live birth is deemed successful (Sunderam et al. 2017; Lathi 
et al. 2012; Tomazevic et al. 2007). Infertility in the form of diminished ovarian reserve (DOR) or 
preliminary ovarian failure (POF) reduces IVF treatment success (Huang and Rosenwaks 2012; 
Sauerbrun-Cutler et al. 2015). Of key importance is that by this measure patients or clinicians are 
unable to discern whether the success was a result of a treatment, in which one pregnancy is 
achieved and five blastocysts may have been cryopreserved or from a treatment, in which one 
pregnancy is achieved but no blastocysts may have been cryopreserved for future use. In DOR and 
POF patients, infertility in the form of depleting ovarian reserve is advancing exponentially 
compared to patients with normal ovarian reserve (Levi et al. 2001). It is, therefore, crucial to 
ensure optimal blastocysts developmental rate for these patients maximally producing a sufficient 
number of blastocysts from one IVF treatment, with which the patient may complete their family 
building. If DOR or POF patients produce only one high quality blastocyst, used for uterine 
transplant, the patient may become pregnant, causing at least 9 months of delay until their next 
IVF treatment attempt for a subsequent pregnancy. During this lapsed time, the patient’s ovarian 
reserve will continue depletion leading to a significant reduction in future IVF treatment success 
(Shahine et al. 2016; Huang and Rosenwaks 2012; Alborzi et al. 2015). Therefore, our primary 
concern and focus was not on pregnancy outcome per treatment, but rather on the percent of high 
quality blastocyst production per treatment to optimize success especially for patients with poor 
prognosis. 
113 
 Culture Conditions, Embryos and Infertility 
Excessive variability in culture conditions, however subtle, jeopardizes the rate of success 
of treatment measured by high quality blastocyst development. Primarily, results of the initial 
analysis on blastocysts development determined correlation with disparity in culture conditions 
observed among incubators. However, these results were dependent on cleavage stage embryo 
development. Interestingly, out-of-range values for pO2 and pCO2 of media did not negatively 
impact blastocysts development rate for all patients in incubators #1 and #3. The patients that were 
impacted were those diagnosed as affected with infertility in the form of DOR or POF as 
determined by the prediction model with cleavage stage embryo development as outcome.  
Oxygen gradients play an important role in tissue development and proper formation of 
vascular structure in the developing embryo and oxygen equilibrium concentration states are 
inversely proportional to cell density in the embryo  (Cochran et al. 2006; Hongbin Liu et al. 2009; 
Wale and Gardner 2016). Mitochondrial activity, as a result is hindered with variation in oxygen 
gradients effecting glycolysis (Saito et al. 2015; Hayashi et al. 2017). Conditions leading to 
lowered cellular metabolism are often induced by smoking, stress, recreational drug use, certain 
prescription drug use and obesity (Lindberg et al. 2016; Osadchuk et al. 2017; Denomme et al. 
2017). Side-effects from drug use and obesity are linked to reproductive disorders leading to 
infertility, hormonal imbalance and impaired cellular function (Alvarez 2015; Beal et al. 2017; 
Morgante et al. 2017).  
As many of the above mentioned factors influence reproductive health their conditions 
seem to have a commonality: roll of cellular metabolism. Cellular metabolism and respiration rely 
heavily on energy produced by the mitochondria used for various cellular activities including 
proper cell growth. Hypoxia and hypoxia-inducible factors (HIF’s) can lead to unfavorable 
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outcomes such production of reactive oxygen species that are toxic byproducts of aerobic 
metabolism leading to embryonic arrest and poor embryo development in the form of apoptosis 
(Sagrillo-Fagundes et al. 2016; Wang et al. 2016). I speculate that in this group of patients’ oxygen 
gradients in vivo, specifically in their reproductive organs, may be dissimilar to patients with 
normal ovarian reserve. Oxygen gradients in the fallopian fluid play a protective role and exert a 
positive effect on reactive oxygen species induced by sperm DNA damage (Belva et al. 2016; De 
Jonge 2017; Abdelbaki et al. 2017). However, the fallopian oxygen gradients and their direct effect 
on developing oocytes for patients with infertility have yet to be studied.  If the conditions of DOR 
or POF do, in fact, result in an altered pO2 gradient in vivo, it is not surprising that continued 
exposure to out-of-range in vitro pO2 would cause harmful effects on early embryo development.  






Medium Batch    Incubator #1 
Out-of-
Range 









 5975 pH 7.41 ± 0.01* +.007 7.39 ± 0.04 n/a 7.38 ± 0.05* +0.04 
G1 Plus 
 
pCO2 28.13 ± 0.52* -3.9 29.97 ± 1.90 n/a 30.97 ± 3.36* -1.0 
 
 
pO2 84.67 ± 12.72 n/a 84.67 ± 13.25 n/a 78.67 ± 8.21* -4.3 
G1 Plus 6209 pH 7.35 ± 0.02 n/a NIU 
 
- - 7.33 ± 0.02 n/a 
 
 
pCO2 31.68 ± 1.43 n/a NIU 
 
- - 32.60 ± 1.65 n/a 
   pO2 69.17 ± 1.25 -14 NIU 
 
- - 70.33 ± 2.75* -12.67 
G2 Plus 5979 pH 7.40 ± 0.10* +0.06 7.49 ± 0.16 n/a 7.54 ± 0.22* +0.14 
 
 
pCO2 28.50 ± 4.95 n/a 25.77 ± 5.76 n/a 25.53 ± 6.80 n/a 
 
 
pO2 72.00 ± 4.73 n/a 82.33 ± 13.84 n/a 89.33 ± 16.86 n/a 
G2 Plus 6213 pH 7.33 ± 0.04 n/a NIU 
 
- - 7.33 ± 0.04 n/a 
 
 
pCO2 30.43 ± 2.87 n/a NIU 
 
- - 31.20 ± 2.93 n/a 
 
 
pO2 65.33 ± 1.67* -17.7 NIU 
 
- - 63.67 ± 4.49* -19.33 
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G2 Plus 6270 pH 7.32 ± 0.00 n/a NIU 
 
- - 7.30 ± 0.00 n/a 
 
 
pCO2 33.33 ± 0.09 n/a NIU 
 
- - 35.53 ± 0.42 n/a 
 
 
pO2 67.00 ± 3.51* -16.0 NIU 
 
- - 68.67 ± 1.20* -15.33 
NIU: Not in use.  
n/a: not applicable 
*Values outside of the normal acceptable ranges are bold. 
Readings were performed using iStat (Abbott) analyzer on equilibrated media 
 
 Embryo Metabolism  
I also evaluated culture methods to further understand this variability in pO2 and pCO2 
readings in incubators using the same medium batch. The number of embryos per patient was 
divided among three culture droplets (40μl in volume each). Patients who had <14 oocytes had 
fewer embryos cultured per drop compared to patients with ≥14 oocytes retrieved. Therefore, 
culture volume was higher per embryo for group A(2˚), where more embryos, to a greater extent 
and more quickly influence the chemistry of the surrounding medium. This may explain why 
patients with ≥14 oocytes retrieved were not negatively impacted given a lower embryo to medium 
volume ratio. The greater collective metabolic activity of cleaving embryos, given they were from 
patients not highly impacted by infertility, further explains good development despite out-of-range 
culture conditions. More embryos per culture drop, collectively utilizing amino acids and other 
nutrients in the medium will lead to greater nutrient turnover (Gardner and Wale 2013; Gardner 
1998; Gardner and Harvey 2015). Embryos created from oocytes or sperm that are exposed to 
primary stressors, such as patient age, genetics, etiology, etc., are at high risk of lowered treatment 
success. Subjecting these embryos to secondary stressors, such as out-of-range culture conditions 
causes vulnerability for embryonic development in the form of morphology, phenotype and 
genotype (Gardner and Kelley 2017). 
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Increased respiration rate is associated with viability in cleavage stage embryos (Tejera et 
al. 2012; Wakeland et al. 2017; Yang et al. 2016). Incubators are set to low oxygen (5% O2) to 
mimic presumed physiological conditions in part because atmospheric oxygen levels will result in 
oxidative stress in the form of free radicals causing lower numbers of high quality blastocysts 
(Bedaiwy et al. 2004; Kelley and Gardner 2016; Y. Yang, Xu, et al. 2016). Glucose, the primary 
nutrient of the blastocyst, is metabolized through aerobic glycolysis and oxidation (Gardner and 
Harvey 2015; Perkel and Madan 2017). Oxygen partial pressure surrounding the blastocysts 
ensures proper regulation of metabolic pathways during development, which ultimately leads to 
successful implantation and live birth. Severe hypoxia (<3.5%) will reduce blastocyst development 
(Fawzy et al. 2017; Guo et al. 2014). Therefore, it is critical that pO2 is within normal range for 
culture of embryos in vitro. Additionally, it is critical that pCO2 is within normal range for G1 Plus 
(bicarbonate buffered) primary culture medium, to ensure optimal pH, in which essential amino 
acids, salts and nutrients are biochemically in an environment where they can be appropriately be 
utilized by the developing embryo. Without this balance, embryo development will be hindered 
resulting in lower quality blastocysts.  
 
 Implications to Patients of Present Study 
Lowered outcome success leads to emotional and financial implications on patients since 
each round of IVF treatment can cost ~$12,000. While some patients are financially secure, others 
may elect to barrow funds either from financial institutions or personal loans from family and 
friends. Lack of success or low number of high quality blastocysts per treatment, especially for the 
patients that have borrowed funds, can lead to emotional trauma with heavy implications on 
patient/partner relationship. Although patients are informed that failure is a possibility prior to 
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treatment, coping with this negative outcome can be a grief-driven and burdensome process. The 
clinical staff and physician directly interact with these patients to assist medically with this 
hardship in the form of scientific explanations for individualized treatment failure and success 
odds of future attempts.  
I accepted my hypothesis that subtle variation in incubator culture conditions can lead to 
poor blastocyst development rate for certain infertility patients who we identified to have low 
ovarian reserve. Additionally, I did not find that the acceptable rages of pH, pCO2 and PO2 are too 
broad. I have instead identified greater influence on blastocyst developmental potential due to 
environmental influence such as subtle variations in incubator performance (producing out-of-
range culture values for pCO2 and pO2) and the interaction with oocytes predisposed to primary in 
vivo stressors, previously described. The treatments impacted by low pCO2 on days 1-3, mainly 
resulted in no success, demonstrating irreparable effects of early phase culture in the subset of 
patients with DOR or POF. Expansion of this study using randomization and blinding to 
embryologists in a multi-center setting would be well worth investigating. A multi-center study 
will be significant to broaden industry understanding on IVF culture systems and perhaps allow 
for individualized culture conditions based on patient diagnosis.  
 
6.5 Conclusion 
It is the ultimate responsibility of embryologists performing human in vitro fertilization to 
provide optimal culture conditions for all gametes and embryos. Subtle variability in culture 
conditions may occur across media batches, even when levels of O2 and CO2 concentrations within 
incubators are held within acceptable ranges. Maintenance of chemical composition in the medium 
is critical in optimization of embryo development. I recommend more frequent quality assurance 
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studies within laboratories to identify intra-laboratory occurrences, which may impact treatment 
outcome and ensure that embryos and oocytes from patients with DOR and POF are cultured in 
incubators with minimal variability especially in since they present as high risk of being negatively 
impacted in the form of decreased rate of high quality blastocysts development by high pO2 and 
low pCO2. Incubators with minimal variability should be reserved for patient presenting with 
diminished ovarian reserve or preliminary implantation failure for optimal outcome since all other 
patient treatments were not impacted. The current study reflects the influence of environmental 
factors on the overall rate of high quality blastocysts development per patient treatment. Frequent 
assessment and analysis of the culture system and laboratory equipment performance are critical 





7.1 Mammalian Embryos and Blastocysts 
From the moment of fertilization, mammalian embryos initiate a cascade of molecular 
pathways, each as a response to its development and environment. An embryo develops from a 
single totipotent cell into its extraordinarily complex system of modules that allows anatomical 
changes in the organism without one module necessarily interfering with other modules.  The 
embryo is complex in that the process of embryogenesis and builds diverse layers of complexity 
including transcription programs, which propagate information from the molecular level to the 
tissues and organs later in development (Edelman et al. 2010; Chitwood et al. 2017; Li et al. 2017). 
Additionally, the embryo builds complexity to its individual systems by linked components 
allowing it to function as a whole system comprising of smaller systems. As the embryo grows, 
cells differentiate (e.g., inner cell mass, trophectoderm) according to chemical gradients and 
transcriptional factors. Post-cavitation, the mammalian embryo (now referred to as blastocyst) is 
adaptive with the capacity to change its behavioral responses to the environment for successful 
growth. The adaptability of blastocysts allows for expression of various phenotypes for one 
genotype relative to its environment. Due to the emergent behaviors and responses dependent upon 
the interactions of various factors in the blastocysts’ environment the study of embryo adaptability 
remains complex, yet intriguing.   
 
 Adaptability with Limitations 
The natural environment for development of the embryo and blastocyst are the fallopian 
tubes and the uterus. The practice of in vitro fertilization (IVF) takes advantage of one of the 
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adaptive attributes of the blastocyst capability to develop outside the body, in culture. The 
blastocyst responds to environmental cues by demonstrating a high degree of developmental 
plasticity in the form of metabolic modulation, gene expression and cell division rate 
(Soundararajan et al. 2015; Price et al. 2003; Denver and Crespi 2006; Agrawal 2001). The success 
of blastocysts grown in culture is ultimately measured by rate of live births per uterine blastocyst 
transfer (Sunderam et al. 2017; Farquhar et al. 2013; Tomazevic et al. 2007; Staessen et al. 2008; 
Heitmann et al. 2013). The growing cleavage stage embryos and eventual blastocysts demonstrate 
plasticity and are able to react to an external input or injury by altering its state or fate (Pollard et 
al. 2017; Bedzhov et al. 2014). 
I challenged blastocyst plasticity in the graft transplant study (Chapter 3) by temporarily 
removing calcium, necessary for cell-to-cell adhesion, from blastocyst culture.  I identified another 
form of adaptive limitations in embryogenesis. In the mouse, induced and stage dependent loss of 
functionality in cell adhesion occurs post-calcium removal from blastocyst culture (Gardner and 
Simón 2017; Bronner 2001; Nagy et al. 2012). The resulting decline in growth was indicative of 
the impact of environmental factors, even in the form of minute exposures, which lead to a cascade 
of chemical events altering the fate of the blastocyst (Yang et al. 2017; Lim et al. 2016). In this 
study, blastocysts were unable to fully recover from the induced stress caused by temporary 
disruption of bonds associated with gap junctions in the trophectoderm. The blastocysts that were 
exposed to calcium-free solution on day-5 compared to day-4 demonstrated adaptability in the 
form of partial re-expansion of the blastocoel. 
Limitations of the blastocysts relative to their environment were also identified in Chapter 
4. In this study, pre-implantation genetic screened euploid blastocysts that exhibited organized 
development were high quality blastocysts. These were selected for uterine transfer. Surprisingly, 
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some “euploid” blastocysts resulted in spontaneous abortion prior to 20 weeks of gestation, 
specifically when array comparative genomic hybridization and small nucleotide polymorphism 
techniques were used. It is likely that a contributing factor in the early miscarriage was due to 
undetected mosaicism or segmental aneuploidy. Previously discussed, array comparative genomic 
hybridization and small nucleotide polymorphism array techniques did not recognize or report 
mosaicism in biopsies analyzed. This indicates the embryonic adaptability limitations that are 
presented with challenges of mosaic cell lines early in development. A pregnancy, confirmed with 
elevated beta-human chorionic gonadotropin levels in blood serum 10 days post euploid embryo 
transfer, followed by spontaneous abortion is characteristic of obstacles associated at the fetal 
genome level. Despite consisting of more than one cell lineage, the mosaic embryo, in theory, can 
overcome conditions that prevent implantation, however, it’s limitation is reached when it could 
no longer grow into a viable fetus and the result is often a spontaneous abortion or a miscarriage. 
This limitation results in early pregnancy loss when the mosaic embryonic genome fails to grow 
into a chimeric organism.  
Embryonic adaptability was identified in Chapter 6. My findings indicated that cleavage 
embryos can adapt to subtle differences in culture pH and partial pressures of CO2 and O2. Day 3 
embryos cultured in incubator 3, which resulted in slight out-of-range values for culture conditions, 
were able to adapt to the change in their environment when not predisposed to primary stressors 
leading to infertility (90% success), like preliminary ovarian failure or diminished ovarian reserve. 
Under the same culture conditions, day 3 embryos of individuals with lower numbers of oocytes 
retrieved (<14) were not able to adapt as well (~20% success) (Chapter 6). Despite plasticity; the 
embryos and blastocysts have their limitations in the form of conditional adaptation. 
The blastocyst can also demonstrate adaptability in the form of chimeric growth. Cheatham 
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et al. (2009) produced chimeras by fusing the embryonic cells of the two mice strains to construct 
a mouse with the desired knock out gene. The individual cells, obtained from two different 
lineages, when placed within proximity in the same blastocyst demonstrated adaptability and 
continued development relative to their neighboring cells into a complete chimeric organism. Cell 
specification, developmental signaling and  cell migration are influenced, in part, by chance 
fluctuations by transcriptional factors, paracrine factors and receptors produced at various times 
throughout development of the blastocyst (Breau and Schneider-Maunoury 2015; Ruvinsky et al. 
2009; Basson 2012). Together with its individual components the developing blastocyst has the 
ability to act independently, creating sub-specialized cell types and can act as a holistic organism 
related to its neighboring modules. In this way, the blastocyst is both complex and adaptive relative 
to the theory of systems biology (Brodland 2015; Plouhinec and De Robertis 2007; Edelman et al. 
2010). Albeit, the blastocyst is endowed with adaptive functionality to environmental challenges, 
the burden to simultaneously maintain homeostasis is considerable. 
 
 Homeostasis – in Vivo and in Vitro 
Homeostasis, whereby the embryo or blastocyst maintains a stable equilibrium with its 
internal components regardless of the conditions found in its environment, is maintained in various 
ways (Swain 2010; Lane and Gardner 2000; Swain et al. 2012). Critical to development is the 
maintenance of ionic homeostasis carried out by  regulation of intercellular pH, calcium ions, 
magnesium ions and phosphate ions (Swain 2012; Lane and Gardner 2000; Dubyak 2004). The 
maintenance of a balance of ions results in proper cell development and function. Embryonic cells 
utilize calcium/potassium pumps embedded in the lipid bi-layer to control the amount of calcium 
and potassium concentrations within the cell cytoplasm and maintain homeostasis (Bavister 2012; 
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Watson and Barcroft 2001).  
Homeostasis for embryos and blastocysts was observed in my studies.  As an example, in 
the cell graft study (Chapter 3), cells were removed from one blastocyst and transferred to a sibling 
blastocyst. This study takes into account the ability of the blastocyst to maintain homeostasis by 
apoptotically removing damaged cells ablated by the Saturn laser during the graft transplant 
procedure. It also shows the blastocysts capacity for homeorhesis in the form of cell graft annealing 
to sibling trophectoderm cells for continued development. As the blastocyst recovered from the 
procedure, the cells functioned independently to maintain cell-to-cell interaction of gap junctions 
by the removal of damaged cells (apoptosis) and attachment of neighboring cells (sibling grafts) 
for survivability and continued viability. Blastocysts were able to successfully maintain 
homeostasis post-treatment under day 4 and day 5, stage-dependent and modified Human Tubal 
Fluid conditions in this study. Blastocysts completely re-expanded their blastocoelic cavity, 
demonstrated symmetry in the trophectoderm and incorporated and integrated sibling graft cells 
(homeorhesis) when treatment was with modified human tubal fluid (mHTF) (E-cadherin-catenin 
bonds not disrupted). The cell ablation and graft transplant procedure did not result in decline in 
blastocyst morphology or reduce viability. However, the disruption of cell adhesion (calcium 
removal) disrupted homeostasis, from which the blastocyst could not recover, exhibiting their 
limitations. 
Homeorhesis takes the change occurring within an organism and within the space-time 
continuum to describe the constant interactions of the organism with its changing environment as 
necessary for the organism’s well being and adaption (Winslow 2017; Gilbert 2000). My studies 
combined both the theory of homeostasis and homeorhesis by evaluating how the embryo 
stabilizes its different components while maintaining development. In Chapter 6, I studied the 
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effects of culture conditions on embryo development and the rate of blastocyst formation with 
respect to the small shifts in pH, partial pressures of carbon dioxide and oxygen throughout culture. 
As an example, in this study, incubator #1 had out-of-range pH by +0.07 in the primary culture 
media (G1 Plus). Although the extracellular pH was higher than expected, embryos were able to 
maintain homeostasis and homeorhesis by demonstrating blastocyst development. The predictive 
modeling analysis determined incubator #1 was insignificant as a factor that influenced a decline 
in blastocysts formation, based on pH differences in culture.  
 
7.2 Limitations of In Vitro Fertilization 
 Rate of Blastocyst Development 
In vitro fertilization treatment outcomes, viewed as rate of blastocysts production per 
treatment, vary among patients. Female patients <35 years old are expected to have a higher rate 
of blastocyst development compared to the patients >40 years (Cohen et al. 2015; Meldrum et al. 
2016; Tomazevic et al. 2007). In Chapter 5, I identified a strong correlation of negative outcome -
rate of blastocysts development- in individuals characterized as “good responders” presenting with 
high AMH values ( ≥3.1 ng/ml) specifically when exposed to high gonadotropin doses (>3325IU) 
during stimulation. According this criteria, the rate of success was 0% (n=11) as determined by 
the decision tree (Chapter 5). Although unexpected, this outcome can be improved by controlling 
secondary stressors to influence outcome as described in the prediction model. 
Age, undoubtedly, is an important factor and a primary-stressor for infertile patients. 
However, in Chapter 6, a greater impact on blastocyst developmental potential was identified when 
age was coupled with low ovarian reserve. Ovarian reserve depletes for women at variable rates. 
Therefore, all 40 year old females will not present with diminished reserve. For example, a female 
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who is 40 years and diagnosed with polycystic ovaries is anovulatory and presents with a normal 
ovarian reserve despite age. This patient is expected to have better prognosis than a patient of the 
same age with elevated basal FSH, ovulatory and low ovarian reserve (Minooee et al. 2017; 
Morgante et al. 2017; van der Meer et al. 1994). Cohen et al. (2015), did not consider the 
magnitude of impact resulting from coupling gametes predisposed to primary stressors (i.e. DOR) 
with multiple secondary stressors (i.e. high gonadotropin doses during ovarian simulation and 
slight out-of-range culture pCO2 and pO2 for embryology). In my studies, coupling of prolonged 
exposure to multiple conditions collectively result in lowered blastocyst developmental potential 
(see Chapters 5 and 6) by depreciating the ability of the blastocyst to adapt to its environment. 
Namely, Chapter 6, blastocysts impacted by low pCO2 on days 1-3, mainly resulted in no success 
for oocytes retrieved from diminished ovarian reserve patients, as mentioned above. 
On average, 40% of fertilized oocytes develop into blastocysts (Zhao et al. 2012; 
Tomazevic et al. 2007; Heitmann et al. 2013), which is a demonstration of their adaptability and 
an indication that blastocysts can thrive in culture with greater success outcome if culture is 
individualized per patient. Individualized culture requires evaluation of primary stressors such as 
patient age, genetics, etiology, etc. In all four of my studies, I identified factors that influence the 
low rate of blastocyst formation per IVF treatment. Extended research analyzing specific metabolic 
events, which lead to attretic, arrested and poorly developed blastocysts are well worth conducting. 
Furthermore, parallel study of variables resulting in high quality blastocysts will allow insight and 
aid in identification of key factors in the molecular processes, which result in favorable 
development. Clinicians routinely individualize gonadotropin doses by patient diagnostics (van 
Tilborg et al. 2016; Andersen et al. 2017; Oudshoorn et al. 2017). The future of IVF will very 
likely involve individualized culture conditions for complete optimization of IVF. 
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 Abandoned Blastocysts 
Controlled ovarian hyperstimulation results in the formation of multiple embryos and 
blastocysts per cycle. Patients struggle with the disposition options available for excess unused 
blastocysts. Once family planning is completed and patient and partner have reached an agreement 
regarding final disposition of excess cryopreserved embryos, the laboratory is notified. One of the 
following options is usually selected by the genetic parents:  any blastocysts remaining in 
cryopreservation storage are discarded (warmed to room temperature and disposed of as medical 
waste), donated to research or anonymously donated to an infertile couple. If the patient and 
partner have not agreed on final disposition of embryos and refuse to communicate with the clinic 
or laboratory regarding a decision, the embryos are considered abandoned. IVF laboratories are 
still facing challenges on how to deal with this dilemma. I strongly encourage the use of the 
decision tree in Chapter 5, which results in minimizing creation of excess blastocysts for good 
prognosis patients presenting with normal ovarian reserve and maximizing this outcome for 
patients presenting with low ovarian reserve. This tailored approach will collectively lower the 
creation of surplus blastocysts. Ultimately, this approach will lessen the patient emotional burden 
associated with the final disposition of cryopreserved embryos. Additionally, laboratories should 
restructure IVF protocols by the use of predictive modeling analysis using their own treatment 
outcomes. I recommend analysis conducted every 2 years. Findings of the prediction model 
specific to site can be compared against Figure 5.1 to ensure reproducibility of the predictive 
model. Standardized ovarian stimulation protocols based on the decision tree analysis can be 
created, which explicitly state medication doses, days of stimulation, etc. to offer the highest 
standards of IVF treatment to infertility patients.  
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 Pre-implantation Genetic Screening 
Preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) 
have been used in IVF to detect unbalanced chromosome copy numbers or single gene disorders 
in blastocysts (Zhu et al. 2014; Aleksandrova et al. 2016; Dahdouh et al. 2015; Fiorentino et al. 
2014; Harper and Harton 2010; Li et al. 2014).  I incorporated three of the widely used methods 
of blastocyst screening offered to patients undergoing IVF in Chapter 4: array comparative 
genomic hybridization (aCGH), small nucleotide polymorphism (SNP) array, and next generation 
sequencing (NGS). No significant difference in pregnancy outcome resulted from euploid-
screened blastocysts by any of the three screening methods in patients 35-37 years of age. 
Importantly, patients < 34 years did not benefit from screening blastocysts using any of the three 
methods identifying limitations to PGS (Chapter 4). It would be well worth investigating 
alternative forms of screening such as methylation patterns in the embryonic genome and 
assessment of mitochondrial DNA in addition to PGS for greater insight on blastocyst genomics. 
Identification of anomalies other than chromosome aberrations in the genome can allow 
optimization for blastocysts selection for uterine transfer. Ultimately, this information will aid in 
the selection of blastocysts with the highest implantation success leading to improved live birth 
rates. 
 
 Evolution of IVF:  Inclusive Embryology 
Ovarian stimulation during IVF treatment often recruits a large number of oocytes. The 
general practice is to identify and utilize the blastocysts that are well developed at the end of the 
treatment by excluding others that demonstrate arrested or attretic morphology. The technique of 
preimplantation genetic screening presents further exclusion of blastocysts that exhibit the 
aforementioned high grade morphology. This exclusion is applied by eliminating aneuploid 
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blastocysts for uterine transfer. Few to no solutions offer potential methods to include poorly 
developed blastocysts. Consequently, they are excluded from selection for uterine transfer or 
cryopreservation procedures. Approaching infertility treatment with an inclusion method will 
assist in achieving higher success for some patients. In Chapter 3, I presented findings, in which I 
applied a novel technique focused on rectification of this issue in a mouse model: graft transfer 
embryonic stem cells (GT-ESC). Specifically, blastocysts that develop a well formed inner cell 
mass but a poorly formed trophectoderm, or vice versa, are blastocysts that would benefit most 
from this technique. Under the right culture conditions, blastocysts are able to integrate donated 
cells from sibling blastocysts into their own TE and exhibit continued development. Given this 
initial success, future studies conducted to examine live birth outcome resulting from sibling graft 
recipient blastocyst in animal models are well worth investigating. In addition to live birth rates, 
studies investigating expression rate of E-Cadherin during various stages of blastocyst 
development during and post graft transplant and offspring health studies from use of such 
blastocysts will pave the way for eventual use of this technique in human IVF. 
 
7.3 Cost Factors 
 Financial Burden 
Monetary costs (to patients or insurance companies) are inevitably associated with IVF 
treatment. However, my findings indicate methods that can lower this burden for patients. 
Importantly, analysis of PGS and pregnancy outcome determined blastocysts from individuals of 
<34 years of age do not benefit from screening. Patients should be counseled appropriately to 
minimize unnecessary biopsy procedures on blastocysts and to minimize costs associated with 
such procedures. Additionally, the predictive model analysis in Chapter 5 provides maximal 
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discrimination between subgroups to determine the values associated with each node on the 
decision tree, referred to as a ‘split rule’, while maintaining high homogeneity within each 
subgroup. The resulting split rules provide a robust decision tree, which should be used as a 
resource to minimize medication dose (total IU), limiting financial burden while maximizing 
outcome of high quality blastocyst development per treatment. Finally, limiting the number of 
surplus blastocysts created per treatment can lower the patient’s financial burden with respect to 
ongoing laboratory storage fees associated with maintaining and monitoring blastocysts in 
cryopreserved state. 
 
 Emotional Burden 
Diminished ovarian reserve (DOR) and preliminary ovarian failure (POF) patients 
represent approximately 30% of the IVF treatments in the United States (Cohen et al. 2015; “ART 
Report 2013-CDC” 2015). These patients are at high risk of developing mosaic blastocysts 
(Capalbo et al. 2017; Munné et al. 1993; Sermon et al. 2016). Proper counsel and screening of 
blastocysts by NGS will identify errors beyond whole chromosome or large segmental deletions 
or duplications.  NGS, identifies mosaicism, thereby reducing the rate of spontaneous abortions 
and ultimately increasing the rate of sustainable pregnancy in individuals with advanced maternal 
age. NGS use for patients >40 years will lessen the emotional burdens that present with 
miscarriages (Chapter 4).  
I also identified that AMH values are reliable indicators of blastocyst developmental 
potential compared to basal FSH values (Chapter 5) that can be used as a tool to properly counsel 
patients seeking IVF treatment. I confirmed that patients with DOR (<12 mature follicles at trigger) 
, POF or poor prognosis exhibit a high rate of good quality blastocyst development per treatment, 
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which positively correlates with increasing levels of gonadotropins inversely related to individuals 
with a higher number of mature follicles at trigger (>12). Utilization of the decision tree for 
blastocysts optimization will further lessen the emotional burden associated with negative 
outcomes for these poor prognosis patients. 
 
7.4 Final Thoughts 
The evidence and understanding of embryology and mechanisms of self-correction of DNA 
errors in early blastocysts are still not well understood. It is important to distinguish between 
organismal survival versus thriving growth. Considering the interactions between many of the 
variables and factors associated with an IVF treatment, blastocysts development outcome can be 
improved with the use of decision trees presented in my studies from stimulation to culture and 
ultimately, blastocysts’ rescue.  As the era of IVF advances to higher technologies (i.e. NGS and 
graft transplants) the burden is on embryologists and clinical researchers to accurately assess their 
findings in a robust inclusive manner accounting for interactions of all variables simultaneously. 
With the advancements in the field statistics using artificial intelligence, research findings are even 
stronger and can produce greater success in the IVF field with accurate predictability. In the end, 
the goal is to optimize care and treatment and provide elite conditions for the success of the patient.
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